A Phase 2 interventional study of Bexsero and Saline Placebo in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 32 sites in 3 countries. Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-27.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is one of 7 in phase 2, and was the 14th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,063 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
71 studies in Meningococcal Infections by GlaxoSmithKline: none open now, 1 under way, none of them phase 3. Of 70 finished, 60 (86%) have results posted.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 15th largest by enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2014, is one of 25 in phase 2, and was the 51st registered.
GlaxoSmithKline’s Meningococcal Infections studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 71 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purposes for conducting the study are firstly to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those of the licensed rMenB+OMV vaccine (Bexsero™) in terms of hSBA GMTs at one month after the second vaccination, secondly to give the flexibility for the national vaccination program by showing the safety and immunogenicity of MenABCWY administrated according to four different vaccination schedules and additionally to evaluate a potential benefit of the 3-dose vaccination series.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
Biological: Bexsero · Other: Saline Placebo · Biological: Havrix
Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY
Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY
Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY
Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
Other: Saline Placebo · Biological: Havrix · Biological: MenABCWY
Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
Biological: Havrix · Biological: MenABCWY
Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.
The non-inferiority of the Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant (MenABCWY) vaccine to Meningococcal (group B) multicomponent recombinant adsorbed (Bexsero) vaccine, administered according to 0, 2 month schedule, as measured by hSBA GMTs against N.meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, is reported. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the rMenB_0_2 and ABCWY_ 0_2 Groups.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)
hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 2 months schedule, as measured by hSBA GMTs against N. meningitidis serogroup B test strains and serogroups A,C, W and Y at 1 month after the last meningococcal vaccination. The B test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the ABCWY_ 0_2 and ABCWY_0_2_6 Groups. 1 month post last meningococcal vaccination corresponds to Month 3 for ABCWY_0_2 Group and Month 7 for ABCWY_0_2_6 Group.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)
Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 2 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)
hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2 months schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.
Time frame: At 1 Month after the last vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group, Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)
Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.
A sufficient immune response following Bexsero vaccine, administered according to 0, 2 month schedule, as measured by the percentage of subjects with hSBA titers ≥ Lower Limit of Quantitation (LLQ) against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, was to be demonstrated. Criterion: the immune response was to be considered sufficient if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA titers ≥ LLQ was greater than 75% for each of the four serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)
hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 6 months schedule, as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.
Time frame: At 1 month after last vaccination (Month 7)
Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 6 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 7)
Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2 month schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.
Time frame: At 1 month after second vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group , Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)
hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the adjusted hSBA GMTs against serogroups A,C, W and Y and serogroup B test strains was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against NZ98/254 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M14459 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M07-0241084 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against 96217 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against A human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against C human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against W human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against Y human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules.
The kinetic of immune response (at Months 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with two-, three- and four-fold titer rise against serogroups A, C, W and Y and serogroup B test strains was assessed. The two/three/four fold titer rise is defined as: a) for subjects with prevaccination hSBA titers ≤ LLQ, a postvaccination hSBA ≥ 2/3/4 LLQ; b) for subjects with a prevaccination hSBA titers ≥ LLQ, an increase of at least 2/3/4 times of the prevaccination hSBA titer.
Time frame: At Month 2, Month 3, Month 7 and Month 13
The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains.
The area under the curve for percentage of subjects with hSBA titers ≥ LLQ for all serogroups (A, C, W and Y) and for all serogroup B test strains (M14459, 96217, NZ98/254 and M07-0241084) was summarized overall (from Month 0 to Month 13) and by period (from Month 0 to Month 2, Month 2 to Month 3, Month 3 to Month 7 and Month 7 to Month 13) by vaccine groups. It was computed as the sum of the trapezoidal areas and the time unit used was the month. AUC 0_13 = (r0+r2)(2-0)/2 + (r2+r3)(3-2)/2 + (r3+r7)(7-3)/2 + (r7+r13)(13-7)/2 with ri = percentages of subjects with both hSBA titers \>= LLQ against N. meningitis for all serogroups A, C, W and Y and for all serogroup B test strains at Month 1.
Time frame: From Month 0 to Month 13
Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination.
Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity within 30 minutes after each vaccination. Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).
Time frame: Within 30 minutes after vaccination
Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination.
An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a participant and/or parent/legal guardian who has signed the informed consent. Number of participants reporting any unsolicited AE within 30 minutes after each vaccination.
Time frame: Within 30 minutes after vaccination
Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination.
The number of participants reporting unsolicited AEs and possibly or probably related unsolicited AEs were assessed.
Time frame: Day 1 through Day 30 after any vaccination
Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.
Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported.
Time frame: At Day 1 (6 hours) to Day 7 after vaccination
Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal
The number of participants reporting any SAE, possibly or probably related SAE(s), medically-attended AEs, AEs leading to premature withdrawal, AEs leading to death, AEs leading to hospitalization and AEs leading to dose reduction, interruption and delay in study vaccination during the entire study period is reported.
Time frame: During the entire study period (Month 0 to Month 13)
Subjects were recruited from 32 centers from Finland, Poland and United States.
| Milestone | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Started | 228 | 232 | 157 | 134 | 152 | 160 |
| Completed | 209 | 211 | 141 | 123 | 137 | 147 |
| Not completed | 19 | 21 | 16 | 11 | 15 | 13 |
| Withdrew: Adverse event | 1 | 2 | 2 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 10 | 8 | 6 | 5 | 4 |
| Withdrew: Lost to follow-up | 6 | 7 | 4 | 1 | 8 | 4 |
| Withdrew: Protocol violation | 2 | 1 | 0 | 1 | 2 | 3 |
| Withdrew: Other | 2 | 1 | 2 | 1 | 0 | 1 |
The non-inferiority of the Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant (MenABCWY) vaccine to Meningococcal (group B) multicomponent recombinant adsorbed (Bexsero) vaccine, administered according to 0, 2 month schedule, as measured by hSBA GMTs against N.meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, is reported. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the rMenB_0_2 and ABCWY_ 0_2 Groups.
| Titers | ABCWY_ 0_2 Group | rMenB_0_2 Group |
|---|---|---|
| M14459 strain (Month 0) | 1.28 (1.07 to 1.53) | 1.31 (1.09 to 1.57) |
| M14459 strain (Month 3) | 11.64 (8.61 to 16) | 15.78 (12 to 22) |
| M07-0241084 strain (Month 0) | 2.12 (1.60 to 2.82) | 2.16 (1.61 to 2.89) |
| M07-0241084 strain (Month 3) | 8.19 (6.31 to 11) | 11.56 (8.86 to 15) |
| 96217 strain (Month 0) | 2.93 (2.13 to 4.03) | 2.36 (1.70 to 3.28) |
| 96217 strain (Month 3) | 150.82 (118 to 192) | 229.29 (179 to 294) |
| NZ98/254 strain (Month 0) | 1.27 (1.06 to 1.53) | 1.15 (0.95 to 1.39) |
| NZ98/254 strain (Month 3) | 11.95 (9.10 to 16) | 24.31 (18 to 32) |
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 2 months schedule, as measured by hSBA GMTs against N. meningitidis serogroup B test strains and serogroups A,C, W and Y at 1 month after the last meningococcal vaccination. The B test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the ABCWY_ 0_2 and ABCWY_0_2_6 Groups. 1 month post last meningococcal vaccination corresponds to Month 3 for ABCWY_0_2 Group and Month 7 for ABCWY_0_2_6 Group.
| Titers | ABCWY_ 0_2 Group | ABCWY_0_2_6 Group |
|---|---|---|
| M14459 strain (Month 0) | 1.21 (1.07 to 1.37) | 1.12 (0.98 to 1.28) |
| M14459 strain (Month 3/Month 7) | 12.17 (9.60 to 15) | 27.09 (21 to 35) |
| M07-0241084 strain (Month 0) | 2.36 (1.85 to 3.01) | 2.05 (1.58 to 2.67) |
| M07-0241084 strain (Month 3/Month 7) | 8.91 (7.10 to 11) | 18.03 (14 to 23) |
| 96217 strain (Month 0) | 2.31 (1.75 to 3.06) | 2.28 (1.68 to 3.07) |
| 96217 strain (Month 3/Month7) | 174.27 (142 to 215) | 298.76 (239 to 374) |
| NZ98/254 strain (Month 0) | 1.24 (1.09 to 1.41) | 1.07 (0.93 to 1.23) |
| NZ98/254 strain (Month 3/Month7) | 12.57 (9.81 to 16) | 17.55 (13 to 23) |
| A human serogroup (Month 0) | 1.19 (1.04 to 1.36) | 1.10 (0.95 to 1.27) |
| A human serogroup (Month 3/Month7) | 66.73 (54 to 83) | 125.45 (99 to 159) |
| C human serogroup (Month 0) | 3.59 (2.85 to 4.53) | 3.19 (2.48 to 4.10) |
| C human serogroup (Month 3/Month7) | 158.8 (127 to 199) | 376.44 (295 to 481) |
| W human serogroup (Month 0) | 5.20 (3.56 to 7.59) | 4.64 (3.05 to 7.05) |
| W human serogroup (Month 3/Month7) | 206.62 (175 to 244) | 295.9 (246 to 356) |
| Y human serogroup (Month 0) | 1.33 (1.10 to 1.60) | 1.26 (1.03 to 1.55) |
| Y human serogroup (Month 3/Month7) | 79.84 (62 to 103) | 163.69 (124 to 216) |
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 2 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination.
| Percentages of subjects | ABCWY_ 0_2 Group | ABCWY_0_2_6 Group |
|---|---|---|
| NZ98/254 strain (Month 0) | 6 (3.37 to 10.45) | 2 (0.41 to 5.70) |
| NZ98/254 strain (Month 3/7) | 63 (55.85 to 69.26) | 74 (65.72 to 80.35) |
| M14459 strain (Month 0) | 5 (2.68 to 9.31) | 2 (0.41 to 5.70) |
| M14459 strain (Month 3/Month 7) | 70 (63.48 to 76.23) | 89 (83.36 to 93.82) |
| M07-0241084 strain (Month 0) | 18 (13.30 to 24.47) | 18 (12.06 to 25.16) |
| M07-0241084 strain (Month 3/7) | 49 (41.54 to 55.59) | 72 (64.35 to 79.33) |
| 96217 strain (Month 0) | 28 (22.24 to 34.99) | 27 (20.02 to 35.11) |
| 96217 strain (Month 3/7) | 97 (93.25 to 98.65) | 99 (96.34 to 99.98) |
| Serogroup A (Month 0) | 3 (1.08 to 6.23) | 1 (0.02 to 3.76) |
| Serogroup A (Month 3/7) | 88 (83.01 to 92.18) | 95 (89.56 to 97.62) |
| Serogroup C (Month 0) | 44 (37.28 to 51.24) | 41 (32.62 to 49.15) |
| Serogroup C (Month 3/7) | 99 (96.63 to 99.89) | 100 (97.55 to 100) |
| Serogroup W (Month 0) | 27 (21.20 to 34.04) | 22 (15.17 to 29.56) |
| Serogroup W (Month 3/7) | 97 (93.19 to 98.64) | 99 (96.08 to 99.98) |
| Serogroup Y (Month 0) | 9 (5.37 to 13.72) | 6 (2.78 to 11.08) |
| Serogroup Y (Month 3/7) | 92 (86.97 to 94.91) | 97 (93.31 to 99.27) |
The immunogenicity of MenABCWY vaccine, administered according to 0, 2 months schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.
| Titers | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group |
|---|---|---|---|---|
| NZ98/254 strain | 12.32 (9.82 to 15) | 6.33 (4.86 to 8.23) | 13.64 (10 to 18) | 15.87 (12 to 21) |
| M14459 strain | 12.72 (10 to 16) | 9.19 (7.11 to 12) | 26.48 (20 to 35) | 29.57 (23 to 39) |
| M07-0241084 strain | 9.15 (7.52 to 11) | 6.59 (5.25 to 8.27) | 15.04 (12 to 19) | 16.22 (13 to 21) |
| 96217 strain | 165.47 (133 to 206) | 117.28 (91 to 151) | 237.89 (182 to 310) | 244.97 (189 to 317) |
| A human serogroup | 69.61 (56 to 87) | 79.87 (62 to 103) | 140.76 (108 to 184) | 162.76 (126 to 211) |
| C human serogroup | 162.57 (132 to 201) | 145.73 (114 to 186) | 225.00 (174 to 290) | 292.61 (227 to 376) |
| W human serogroup | 215.72 (182 to 256) | 197.69 (162 to 241) | 376.03 (306 to 462) | 531.79 (434 to 652) |
| Y human serogroup | 71.66 (55 to 93) | 57.45 (42 to 78) | 120.76 (88 to 166) | 209.53 (153 to 286) |
A sufficient immune response following Bexsero vaccine, administered according to 0, 2 month schedule, as measured by the percentage of subjects with hSBA titers ≥ Lower Limit of Quantitation (LLQ) against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, was to be demonstrated. Criterion: the immune response was to be considered sufficient if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA titers ≥ LLQ was greater than 75% for each of the four serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group |
|---|---|---|
| NZ98/254 strain - month 0 (LLQ = 8.2) | 7 (3.73 to 11.53) | 6 (3.40 to 11.06) |
| NZ98/254 strain - month 3 (LLQ = 8.2) | 88 (82.82 to 92.52) | 61 (53.65 to 68.15) |
| M14459 strain - month 0 (LLQ = 8.0) | 7 (3.41 to 11.11) | 5 (2.32 to 9.33) |
| M14459 strain - month 3 (LLQ = 8.0) | 82 (75.75 to 87.32) | 68 (60.21 to 74.39) |
| M07-0241084 strain - month 0 (LLQ = 8.9) | 21 (15.19 to 27.25) | 18 (12.78 to 24.69) |
| M07-0241084 strain - month 3 (LLQ = 8.9) | 66 (59.26 to 73.19) | 47 (39.60 to 54.81) |
| 96217 strain - month 0 (LLQ = 8.6) | 23 (17.26 to 29.85) | 29 (22.14 to 35.89) |
| 96217 strain - month 3 (LLQ = 8.6) | 99 (97.04 to 99.99) | 97 (92.81 to 98.75) |
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 6 months schedule, as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.
| Titers | ABCWY_0_6 Group | ABCWY_0_2_6 Group |
|---|---|---|
| NZ98/254 strain | 13.62 (9.98 to 19) | 17.13 (13 to 23) |
| M14459 strain | 27.82 (21 to 36) | 29.27 (23 to 37) |
| M07-0241084 strain | 17.43 (13 to 23) | 20.92 (16 to 27) |
| 96217 strain | 240.13 (186 to 310) | 291.63 (232 to 367) |
| Serogroup A | 140.14 (107 to 184) | 128.75 (101 to 164) |
| Serogroup C | 246.48 (191 to 318) | 413.60 (328 to 522) |
| Serogroup W | 341.90 (283 to 413) | 282.74 (237 to 338) |
| Serogroup Y | 123.96 (91 to 169) | 151.36 (115 to 200) |
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 6 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.
| Percentages of subjects | ABCWY_0_6 Group | ABCWY_0_2_6 Group |
|---|---|---|
| NZ98/254 strain - month 0 (LLQ=8.2) | 5 (1.86 to 10.57) | 2 (0.41 to 5.70) |
| NZ98/254 strain - month 7 (LLQ=8.2) | 64 (55.25 to 72.95) | 74 (65.72 to 80.35) |
| M14459 strain - month 0 (LLQ=8.0) | 5 (1.84 to 10.48) | 2 (0.41 to 5.70) |
| M14459 strain - month 7 (LLQ=8.0) | 87 (79.58 to 92.31) | 89 (83.36 to 93.82) |
| M07-0241084 strain - month 0 (LLQ=8.9) | 14 (8.33 to 21.37) | 18 (12.06 to 25.16) |
| M07-0241084 strain - month 7 (LLQ=8.9) | 66 (56.76 to 74.16) | 72 (64.35 to 79.33) |
| 96217 strain - month 0 (LLQ=8.6) | 27 (19.18 to 35.79) | 27 (20.02 to 35.11) |
| 996217 strain - month 7 (LLQ=8.6) | 98 (92.93 to 99.49) | 99 (96.34 to 99.98) |
| A human serogroup - month 0 (LLQ=22.7) | 2 (0.21 to 5.99) | 1 (0.02 to 3.76) |
| A human serogroup - month 7 (LLQ=22.7) | 94 (88.63 to 97.68) | 95 (89.56 to 97.62) |
| C human serogroup - month 0 (LLQ=5.2) | 42 (32.94 to 51.07) | 41 (32.62 to 49.15) |
| C human serogroup - month 7 (LLQ=5.2) | 99 (95.55 to 99.98) | 100 (97.55 to 100) |
| W human serogroup - month 0 (LLQ=39.6) | 20 (13.37 to 28.51) | 22 (15.17 to 29.56) |
| W human serogroup -month 7 (LLQ=39.6) | 99 (95.55 to 99.98) | 99 (96.08 to 99.98) |
| Y human serogroup - month 0 (LLQ=14.7) | 7 (2.92 to 12.71) | 6 (2.78 to 11.08) |
| Y human serogroup - month 7 (LLQ=14.7) | 94 (88.63 to 97.68) | 97 (93.31 to 99.27) |
The immunogenicity of MenABCWY vaccine, administered according to 0, 2 month schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.
| Percentages of subjects | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group |
|---|---|---|---|---|
| NZ98/254 strain (LLQ=8.2) | 63 (55.85 to 69.26) | 44 (35.36 to 52.23) | 64 (55.25 to 72.95) | 73 (64.85 to 80.63) |
| M14459 strain (LLQ=8.0) | 70 (63.48 to 76.23) | 62 (53.56 to 70.20) | 87 (79.58 to 92.31) | 89 (82.08 to 93.55) |
| M07-0241084 strain (LLQ=8.9) | 49 (41.54 to 55.59) | 40 (31.82 to 48.61) | 66 (56.76 to 74.16) | 69 (60.82 to 77.21) |
| 96217 strain (LLQ=8.6) | 97 (93.25 to 98.65) | 97 (92.99 to 99.23) | 98 (92.93 to 99.49) | 98 (93.55 to 99.53) |
| Serogroup A (LLQ=22.7) | 88 (83.01 to 92.18) | 92 (85.70 to 95.56) | 94 (88.63 to 97.68) | 94 (88.49 to 97.37) |
| Serogroup C (LLQ=5.2) | 99 (96.63 to 99.89) | 100 (97.44 to 100) | 99 (95.55 to 99.99) | 100 (97.22 to 100) |
| Serogroup W (LLQ=39.6) | 97 (93.19 to 98.64) | 96 (91.09 to 98.44) | 99 (95.55 to 99.98) | 98 (93.45 to 99.53) |
| Serogroup Y (LLQ=14.7) | 92 (86.97 to 94.91) | 85 (78.29 to 90.61) | 94 (88.63 to 97.68) | 97 (92.42 to 99.17) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the adjusted hSBA GMTs against serogroups A,C, W and Y and serogroup B test strains was assessed.
| Titers | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| NZ98/254 strain (Month 0) | 1.22 (1.08 to 1.38) | 1.22 (1.08 to 1.38) | 1.21 (1.04 to 1.40) | 1.13 (0.97 to 1.31) | 1.12 (0.97 to 1.29) | 1.06 (0.93 to 1.22) |
| NZ98/254 strain (Month 2) | 2.67 (2.14 to 3.34) | 2.27 (1.82 to 2.84) | 6.50 (4.98 to 8.48) | 1.92 (1.46 to 2.51) | 3.87 (2.98 to 5.01) | 2.20 (1.71 to 2.82) |
| NZ98/254 strain (Month 3) | 27.17 (22 to 34) | 11.46 (9.28 to 14) | 3.15 (2.44 to 4.05) | 1.69 (1.31 to 2.19) | 2.38 (1.86 to 3.05) | 12.80 (10 to 16) |
| NZ98/254 strain (Month 7) | 3.00 (2.44 to 3.67) | 2.41 (1.97 to 2.95) | 1.88 (1.47 to 2.40) | 14.30 (11 to 18) | 1.75 (1.38 to 2.22) | 18.24 (14 to 23) |
| NZ98/254 strain (Month 13) | 2.33 (1.92 to 2.83) | 1.93 (1.59 to 2.33) | 1.81 (1.44 to 2.27) | 2.57 (2.04 to 3.25) | 17.08 (14 to 21) | 2.82 (2.28 to 3.51) |
| M14459 strain(Month 0) | 1.37 (1.21 to 1.56) | 1.22 (1.08 to 1.39) | 1.22 (1.04 to 1.42) | 1.21 (1.04 to 1.41) | 1.34 (1.15 to 1.55) | 1.17 (1.02 to 1.35) |
| M14459 strain (Month 2) | 2.83 (2.31 to 3.46) | 2.55 (2.08 to 3.13) | 9.23 (7.21 to 12) | 2.34 (1.82 to 2.99) | 3.94 (3.11 to 4.98) | 2.40 (1.92 to 3.01) |
| M14459 strain (Month 3) | 18.29 (15 to 23) | 12.85 (10 to 16) | 5.30 (4.04 to 6.93) | 2.15 (1.64 to 2.82) | 3.11 (2.40 to 4.02) | 15.24 (12 to 20) |
| M14459 strain (Month 7) | 3.52 (2.91 to 4.26) | 3.24 (2.68 to 3.93) | 2.19 (1.74 to 2.77) | 27.47 (22 to 35) | 1.95 (1.56 to 2.43) | 28.56 (23 to 35) |
| M14459 strain (Month 13) | 2.46 (2.03 to 2.97) | 2.29 (1.89 to 2.78) | 1.95 (1.54 to 2.45) | 3.22 (2.55 to 4.06) | 29.01 (23 to 36) | 3.17 (2.57 to 3.92) |
| M07-0241084 strain (Month 0) | 2.26 (1.81 to 2.82) | 2.07 (1.65 to 2.59) | 2.01 (1.53 to 2.63) | 2.06 (1.57 to 2.71) | 2.59 (1.99 to 3.37) | 1.83 (1.42 to 2.36) |
| M07-0241084 strain (Month 2) | 5.09 (4.26 to 6.07) | 4.30 (3.59 to 5.14) | 6.73 (5.44 to 8.34) | 3.51 (2.83 to 4.35) | 4.90 (3.97 to 6.04) | 4.20 (3.43 to 5.15) |
| M07-0241084 strain(Month 3) | 13.91 (12 to 17) | 8.82 (7.29 to 11) | 4.39 (3.49 to 5.50) | 3.30 (2.62 to 4.15) | 3.55 (2.84 to 4.43) | 9.29 (7.49 to 12) |
| M07-0241084 strain (Month 7) | 5.42 (4.51 to 6.51) | 4.68 (3.88 to 5.63) | 3.36 (2.69 to 4.20) | 15.70 (13 to 20) | 2.96 (2.38 to 3.67) | 19.18 (16 to 24) |
| M07-0241084 strain(Month 13) | 4.45 (3.71 to 5.35) | 4.01 (3.34 to 4.83) | 3.07 (2.46 to 3.83) | 5.42 (4.33 to 6.77) | 15.68 (13 to 19) | 5.80 (4.70 to 7.16) |
| 96217 strain (Month 0) | 2.32 (1.82 to 2.95) | 2.84 (2.23 to 3.62) | 2.88 (2.16 to 3.83) | 2.39 (1.78 to 3.21) | 2.78 (2.11 to 3.68) | 2.57 (1.94 to 3.40) |
| 96217 strain(Month 2) | 16.48 (13 to 21) | 11.62 (8.96 to 15) | 124.75 (92 to 169) | 11.61 (8.49 to 16) | 11.94 (8.87 to 16) | 8.54 (6.33 to 12) |
| 96217 strain(Month 3) | 263.56 (211 to 329) | 169.65 (136 to 212) | 82.23 (63 to 107) | 8.61 (6.57 to 11) | 7.72 (5.97 to 9.99) | 162.27 (125 to 210) |
| 96217 strain (Month 7) | 61.46 (50 to 75) | 43.01 (35 to 53) | 37.26 (29 to 47) | 264.85 (207 to 340) | 5.19 (4.10 to 6.58) | 306.14 (242 to 388) |
| 96217 strain (Month 13) | 33.07 (27 to 41) | 22.48 (18 to 28) | 24.00 (18 to 31) | 42.27 (32 to 55) | 264.32 (205 to 341) | 47.22 (37 to 61) |
| Serogroup A (Month 0) | 1.37 (1.18 to 1.59) | 1.17 (1.02 to 1.36) | 1.38 (1.15 to 1.65) | 1.08 (0.90 to 1.30) | 1.19 (1.00 to 1.41) | 1.06 (0.90 to 1.25) |
| Serogroup A (Month 2) | 4.05 (2.97 to 5.54) | 8.35 (6.14 to 11) | 85.49 (59 to 125) | 7.64 (5.22 to 11) | 22.54 (16 to 32) | 5.18 (3.65 to 7.34) |
| Serogroup A (Month 3) | 106.70 (82 to 139) | 68.85 (53 to 89) | 52.42 (38 to 72) | 5.31 (3.86 to 7.31) | 8.77 (6.49 to 12) | 78.30 (58 to 105) |
| Serogroup A (Month 7) | 14.15 (11 to 19) | 11.49 (8.71 to 15) | 9.88 (7.04 to 14) | 165.14 (117 to 233) | 3.25 (2.35 to 4.49) | 140.73 (103 to 193) |
| Serogroup A (Month 13) | 5.80 (4.30 to 7.82) | 4.64 (3.45 to 6.23) | 5.90 (4.11 to 8.46) | 15.20 (11 to 22) | 168.23 (119 to 238) | 13.32 (9.52 to 19) |
| Serogroup C (Month 0) | 3.46 (2.76 to 4.33) | 3.38 (2.71 to 4.23) | 3.87 (2.96 to 5.04) | 3.36 (2.56 to 4.40) | 3.80 (2.92 to 4.94) | 2.99 (2.32 to 3.87) |
| Serogroup C (Month 2) | 9.47 (7.18 to 13) | 31.56 (24 to 42) | 163.28 (118 to 227) | 37.24 (27 to 52) | 54.75 (40 to 76) | 40.29 (29 to 55) |
| Serogroup C (Month 3) | 41.25 (32 to 52) | 184.05 (145 to 234) | 119.71 (90 to 159) | 31.50 (24 to 42) | 41.15 (31 to 54) | 236.97 (180 to 312) |
| Serogroup C (Month 7) | 11.03 (8.81 to 14) | 80.70 (65 to 101) | 76.97 (59 to 100) | 260.57 (199 to 342) | 24.59 (19 to 32) | 476.44 (369 to 615) |
| Serogroup C (Month 13) | 8.45 (6.79 to 11) | 37.45 (30 to 47) | 38.42 (30 to 50) | 57.48 (44 to 75) | 303.63 (235 to 392) | 113.72 (89 to 146) |
| Serogroup W (Month 0) | 6.43 (4.46 to 9.27) | 4.75 (3.35 to 6.73) | 4.54 (2.98 to 6.90) | 4.29 (2.80 to 6.58) | 4.95 (3.30 to 7.44) | 4.46 (2.97 to 6.69) |
| Serogroup W (Month 2) | 17.43 (13 to 23) | 50.71 (39 to 66) | 175.57 (128 to 241) | 59.37 (43 to 82) | 94.34 (69 to 128) | 47.54 (35 to 65) |
| Serogroup W (Month 3) | 138.43 (111 to 173) | 214.70 (173 to 266) | 125.70 (97 to 162) | 59.26 (46 to 77) | 86.66 (68 to 111) | 200.91 (157 to 258) |
| Serogroup W (Month 7) | 22.53 (18 to 29) | 79.96 (63 to 101) | 74.84 (57 to 99) | 340.85 (256 to 453) | 58.19 (44 to 76) | 270.12 (206 to 354) |
| Serogroup W (Month 13) | 12.63 (9.86 to 16) | 45.63 (36 to 58) | 46.83 (35 to 62) | 96.43 (72 to 129) | 478.73 (363 to 631) | 95.90 (73 to 126) |
| Serogroup Y (Month 0) | 1.72 (1.41 to 2.10) | 1.40 (1.14 to 1.71) | 1.68 (1.32 to 2.13) | 1.24 (0.97 to 1.59) | 1.79 (1.42 to 2.25) | 1.34 (1.07 to 1.67) |
| Serogroup Y (Month 2) | 2.36 (1.72 to 3.23) | 19.43 (14 to 27) | 63.45 (44 to 93) | 16.41 (11 to 24) | 27.00 (19 to 39) | 19.82 (14 to 28) |
| Serogroup Y (Month 3) | 3.12 (2.34 to 4.17) | 90.61 (68 to 121) | 42.97 (30 to 61) | 15.95 (11 to 23) | 18.76 (13 to 26) | 97.12 (70 to 134) |
| Serogroup Y (Month 7) | 2.44 (1.87 to 3.17) | 34.27 (26 to 45) | 27.86 (20 to 38) | 152.73 (111 to 211) | 14.29 (11 to 19) | 180.33 (135 to 242) |
| Serogroup Y (Month 13) | 2.28 (1.75 to 2.96) | 18.13 (14 to 24) | 15.19 (11 to 21) | 42.14 (31 to 58) | 231.39 (171 to 313) | 53.78 (40 to 72) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against NZ98/254 B strain was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| NZ98/254 Strain (At Month 0) ≥ LLQ (8.2) | 7 (3.73 to 11.53) | 6 (3.40 to 11.06) | 6 (2.38 to 11.65) | 5 (1.99 to 11.30) | 4 (1.30 to 9.02) | 2 (0.46 to 6.40) |
| NZ98/254 Strain (At Month 0) ≥ 5 | 9 (4.94 to 13.45) | 7 (3.79 to 11.72) | 7 (2.92 to 12.71) | 5 (1.99 to 11.30) | 6 (2.26 to 11.11) | 3 (0.82 to 7.47) |
| NZ98/254 Strain (At Month 0) ≥ 8 | 7 (4.13 to 12.18) | 6 (3.40 to 11.06) | 6 (2.38 to 11.65) | 5 (1.99 to 11.30) | 4 (1.30 to 9.02) | 2 (0.46 to 6.40) |
| NZ98/254 Strain (At Month 0) ≥ 16 | 4 (1.85 to 8.21) | 5 (2.62 to 9.72) | 4 (1.37 to 9.46) | 4 (0.98 to 8.89) | 2 (0.19 to 5.62) | 1 (0.02 to 4.09) |
| NZ98/254 Strain (At Month 0) ≥ 32 | 2 (0.33 to 4.59) | 3 (0.88 to 6.19) | 3 (0.52 to 7.13) | 1 (0.02 to 4.87) | 0 (0 to 2.89) | 0 (0 to 2.72) |
| NZ98/254 Strain (At Month 0) ≥ 64 | 0 (0 to 1.94) | 3 (0.34 to 4.67) | 0 (0 to 3.03) | 1 (0.02 to 4.87) | 0 (0 to 2.89) | 0 (0 to 2.72) |
| NZ98/254 Strain (At Month 0) ≥ 128 | 0 (0 to 1.94) | 0 (0 to 1.97) | 0 (0 to 3.03) | 0 (0 to 3.24) | 0 (0 to 2.89) | 0 (0 to 2.72) |
| NZ98/254 Strain (At Month 2) ≥ LLQ (8.2) | 23 (17.55 to 30.12) | 20 (14.49 to 26.50) | 43 (33.53 to 51.85) | 17 (10.53 to 25.22) | 27 (19.47 to 35.62) | 18 (11.83 to 25.47) |
| NZ98/254 Strain (At Month 2) ≥ 5 | 29 (22.86 to 36.32) | 24 (18.33 to 31.16) | 58 (48.98 to 67.26) | 18 (11.26 to 26.22) | 36 (27.38 to 44.74) | 20 (13.72 to 27.95) |
| NZ98/254 Strain (At Month 2) ≥ 8 | 23 (17.55 to 30.12) | 20 (14.49 to 26.50) | 43 (33.53 to 51.85) | 17 (10.53 to 25.22) | 28 (20.17 to 36.46) | 18 (11.83 to 25.47) |
| NZ98/254 Strain (At Month 2) ≥ 16 | 19 (13.79 to 25.51) | 15 (10.30 to 21.13) | 28 (20.49 to 37.28) | 11 (5.66 to 17.97) | 23 (15.99 to 31.35) | 13 (7.57 to 19.53) |
| NZ98/254 Strain (At Month 2) ≥ 32 | 15 (10.13 to 20.80) | 10 (5.87 to 14.94) | 20 (13.25 to 28.28) | 9 (4.36 to 15.81) | 17 (10.62 to 24.34) | 7 (3.64 to 13.30) |
| NZ98/254 Strain (At Month 2) ≥ 64 | 9 (4.94 to 13.45) | 7 (3.79 to 11.72) | 12 (6.53 to 18.80) | 4 (0.98 to 8.89) | 13 (7.44 to 19.80) | 2 (0.46 to 6.40) |
| NZ98/254 Strain (At Month 2) ≥ 128 | 2 (0.33 to 4.59) | 5 (2.25 to 9.03) | 5 (1.86 to 10.57) | 3 (0.56 to 7.63) | 6 (2.78 to 12.13) | 1 (0.18 to 5.29) |
| NZ98/254 Strain (At Month 3) ≥ LLQ (8.2) | 88 (82.82 to 92.52) | 61 (53.65 to 68.15) | 30 (21.98 to 39.04) | 14 (8.39 to 22.16) | 20 (13.27 to 27.88) | 68 (59.30 to 75.71) |
| NZ98/254 Strain (At Month 3) ≥ 5 | 94 (89.12 to 96.66) | 76 (68.84 to 81.67) | 38 (29.61 to 47.65) | 17 (10.53 to 25.22) | 27 (19.47 to 35.62) | 78 (70.42 to 85.00) |
| NZ98/254 Strain (At Month 3) ≥ 8 | 88 (82.82 to 92.52) | 63 (55.30 to 69.69) | 30 (21.98 to 39.04) | 14 (8.39 to 22.16) | 21 (13.94 to 28.75) | 69 (60.86 to 77.07) |
| NZ98/254 Strain (At Month 3) ≥ 16 | 74 (67.05 to 80.05) | 44 (37.04 to 51.79) | 18 (11.86 to 26.43) | 11 (5.66 to 17.97) | 14 (8.69 to 21.63) | 46 (37.62 to 55.08) |
| NZ98/254 Strain (At Month 3) ≥ 32 | 50 (42.64 to 57.36) | 23 (17.36 to 30.00) | 13 (7.17 to 19.78) | 5 (1.99 to 11.30) | 10 (5.02 to 16.05) | 19 (12.45 to 26.30) |
| NZ98/254 Strain (At Month 3) ≥ 64 | 29 (22.86 to 36.32) | 12 (7.60 to 17.45) | 6 (2.38 to 11.65) | 4 (0.98 to 8.89) | 6 (2.26 to 11.11) | 14 (8.76 to 21.25) |
| NZ98/254 Strain (At Month 3) ≥ 128 | 12 (7.48 to 17.18) | 6 (3.40 to 11.06) | 4 (1.37 to 9.46) | 2 (0.22 to 6.30) | 4 (1.30 to 9.02) | 4 (1.66 to 9.49) |
| NZ98/254 Strain (At Month 7) ≥ LLQ (8.2) | 27 (20.43 to 33.52) | 19 (14.02 to 25.91) | 14 (8.47 to 21.71) | 63 (53.76 to 72.29) | 13 (7.44 to 19.80) | 72 (64.00 to 79.76) |
| NZ98/254 Strain (At Month 7) ≥ 5 | 33 (26.31 to 40.19) | 27 (20.77 to 34.03) | 18 (11.86 to 26.43) | 80 (71.78 to 87.26) | 17 (11.28 to 25.23) | 82 (74.53 to 88.17) |
| NZ98/254 Strain (At Month 7) ≥ 8 | 27 (20.43 to 33.52) | 20 (14.49 to 26.50) | 14 (8.47 to 21.71) | 69 (59.30 to 77.17) | 13 (7.44 to 19.80) | 74 (65.59 to 81.08) |
| NZ98/254 Strain (At Month 7) ≥ 16 | 21 (15.19 to 27.25) | 14 (9.39 to 19.91) | 12 (6.53 to 18.80) | 46 (36.10 to 55.22) | 10 (5.02 to 16.05) | 55 (46.40 to 63.82) |
| NZ98/254 Strain (At Month 7) ≥ 32 | 12 (7.92 to 17.79) | 10 (6.30 to 15.57) | 9 (4.67 to 15.81) | 26 (18.08 to 35.03) | 4 (1.30 to 9.02) | 34 (25.66 to 42.25) |
| NZ98/254 Strain (At Month 7) ≥ 64 | 6 (3.34 to 10.88) | 6 (3.40 to 11.06) | 6 (2.38 to 11.65) | 13 (7.69 to 21.13) | 2 (0.19 to 5.62) | 16 (10.58 to 23.80) |
| NZ98/254 Strain (At Month 7) ≥ 128 | 2 (0.33 to 4.59) | 4 (1.53 to 7.64) | 5 (1.86 to 10.57) | 7 (3.13 to 13.59) | 1 (0.02 to 4.34) | 5 (2.13 to 10.47) |
| NZ98/254 Strain (At Month 13) ≥ LLQ (8.2) | 21 (15.19 to 27.25) | 16 (11.22 to 22.33) | 15 (9.14 to 22.67) | 18 (11.26 to 26.22) | 73 (64.38 to 80.53) | 19 (13.08 to 27.12) |
| NZ98/254 Strain (At Month 13) ≥ 5 | 27 (20.43 to 33.52) | 19 (14.02 to 25.91) | 16 (9.81 to 23.62) | 28 (19.64 to 36.93) | 85 (77.46 to 90.67) | 25 (17.60 to 32.81) |
| NZ98/254 Strain (At Month 13) ≥ 8 | 21 (15.19 to 27.25) | 16 (11.22 to 22.33) | 15 (9.14 to 22.67) | 18 (11.26 to 26.22) | 74 (65.23 to 81.24) | 19 (13.08 to 27.12) |
| NZ98/254 Strain (At Month 13) ≥ 16 | 15 (10.13 to 20.80) | 12 (8.05 to 18.07) | 8 (4.07 to 14.79) | 12 (6.33 to 19.03) | 49 (40.19 to 58.26) | 14 (8.76 to 21.25) |
| NZ98/254 Strain (At Month 13) ≥ 32 | 7 (4.13 to 12.18) | 7 (3.79 to 11.72) | 8 (3.49 to 13.76) | 8 (3.74 to 14.71) | 30 (22.31 to 38.97) | 4 (1.66 to 9.49) |
| NZ98/254 Strain (At Month 13) ≥ 64 | 3 (0.87 to 6.10) | 5 (2.25 to 9.03) | 5 (1.86 to 10.57) | 5 (1.99 to 11.30) | 13 (8.06 to 20.72) | 3 (0.82 to 7.47) |
| NZ98/254 Strain (At Month 13) ≥ 128 | 2 (0.33 to 4.59) | 3 (0.88 to 6.19) | 3 (0.92 to 8.31) | 3 (0.56 to 7.63) | 6 (2.78 to 12.13) | 2 (0.46 to 6.40) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M14459 B strain was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| M14459 Strain (At Month 0) ≥ LLQ (8.0) | 7 (3.41 to 11.11) | 5 (2.32 to 9.33) | 6 (2.55 to 12.45) | 4 (1.02 to 9.21) | 7 (2.85 to 12.41) | 2 (0.46 to 6.40) |
| M14459 Strain (At Month 0) ≥ 5 | 12 (7.65 to 17.54) | 7 (3.92 to 12.10) | 6 (2.55 to 12.45) | 6 (2.65 to 12.90) | 11 (6.36 to 18.36) | 4 (1.22 to 8.49) |
| M14459 Strain (At Month 0) ≥ 8 | 7 (3.41 to 11.11) | 5 (2.32 to 9.33) | 6 (2.55 to 12.45) | 4 (1.02 to 9.21) | 7 (2.85 to 12.41) | 2 (0.46 to 6.40) |
| M14459 Strain (At Month 0) ≥ 16 | 3 (0.89 to 6.23) | 2 (0.35 to 4.82) | 2 (0.22 to 6.30) | 3 (0.58 to 7.90) | 2 (0.51 to 6.96) | 1 (0.18 to 5.29) |
| M14459 Strain (At Month 0) ≥ 32 | 2 (0.34 to 4.69) | 0 (0 to 2.04) | 1 (0.02 to 4.87) | 1 (0.02 to 5.05) | 0 (0 to 2.95) | 1 (0.02 to 4.09) |
| M14459 Strain (At Month 0) ≥ 64 | 1 (0.13 to 3.87) | 0 (0 to 2.04) | 0 (0 to 3.24) | 0 (0 to 3.36) | 0 (0 to 2.95) | 1 (0.02 to 4.09) |
| M14459 Strain (At Month 0) ≥ 128 | 0 (0 to 1.98) | 0 (0 to 2.04) | 0 (0 to 3.24) | 0 (0 to 3.36) | 0 (0 to 2.95) | 0 (0 to 2.72) |
| M14459 Strain (At Month 2) ≥ LLQ (8.0) | 28 (21.88 to 35.35) | 24 (17.96 to 30.96) | 61 (51.04 to 69.81) | 17 (10.19 to 25.06) | 34 (25.84 to 43.24) | 17 (11.20 to 24.63) |
| M14459 Strain (At Month 2) ≥ 5 | 38 (30.49 to 44.92) | 30 (23.03 to 36.88) | 75 (65.93 to 82.70) | 26 (17.97 to 35.25) | 42 (33.42 to 51.51) | 22 (15.64 to 30.39) |
| M14459 Strain (At Month 2) ≥ 8 | 28 (21.88 to 35.35) | 24 (17.96 to 30.96) | 61 (51.04 to 69.81) | 17 (10.19 to 25.06) | 34 (25.84 to 43.24) | 17 (11.20 to 24.63) |
| M14459 Strain (At Month 2) ≥ 16 | 17 (11.74 to 23.05) | 13 (8.32 to 18.65) | 34 (25.25 to 43.48) | 11 (5.87 to 18.06) | 25 (17.81 to 33.83) | 12 (6.98 to 18.67) |
| M14459 Strain (At Month 2) ≥ 32 | 9 (5.05 to 13.74) | 6 (3.11 to 10.73) | 19 (12.00 to 27.22) | 6 (2.07 to 11.70) | 13 (7.62 to 20.26) | 5 (2.13 to 10.47) |
| M14459 Strain (At Month 2) ≥ 64 | 4 (1.90 to 8.39) | 2 (0.61 to 5.62) | 4 (0.98 to 8.89) | 2 (0.23 to 6.53) | 8 (3.97 to 14.44) | 2 (0.46 to 6.40) |
| M14459 Strain (At Month 2) ≥ 128 | 1 (0.01 to 2.99) | 2 (0.35 to 4.82) | 2 (0.22 to 6.30) | 1 (0.02 to 5.05) | 5 (1.81 to 10.32) | 1 (0.18 to 5.29) |
| M14459 Strain (At Month 3) ≥ LLQ (8.0) | 82 (75.75 to 87.32) | 68 (60.21 to 74.39) | 44 (34.39 to 53.44) | 16 (9.45 to 24.00) | 28 (20.69 to 37.29) | 73 (64.80 to 80.42) |
| M14459 Strain (At Month 3) ≥ 5 | 84 (78.16 to 89.18) | 74 (66.66 to 80.03) | 54 (44.78 to 63.90) | 20 (13.23 to 29.20) | 35 (26.58 to 44.08) | 80 (72.05 to 86.28) |
| M14459 Strain (At Month 3) ≥ 8 | 82 (75.75 to 87.32) | 68 (60.21 to 74.39) | 44 (34.39 to 53.44) | 16 (9.45 to 24.00) | 28 (20.69 to 37.29) | 73 (64.80 to 80.42) |
| M14459 Strain (At Month 3) ≥ 16 | 66 (58.98 to 73.09) | 51 (43.83 to 58.92) | 24 (16.53 to 33.10) | 9 (4.53 to 16.37) | 18 (11.56 to 25.82) | 51 (41.98 to 59.48) |
| M14459 Strain (At Month 3) ≥ 32 | 39 (32.03 to 46.58) | 30 (23.54 to 37.46) | 6 (2.55 to 12.45) | 4 (1.02 to 9.21) | 9 (4.55 to 15.44) | 28 (20.91 to 36.79) |
| M14459 Strain (At Month 3) ≥ 64 | 18 (12.68 to 24.25) | 11 (6.51 to 16.08) | 3 (0.56 to 7.63) | 1 (0.02 to 5.05) | 4 (1.33 to 9.23) | 10 (5.83 to 16.91) |
| M14459 Strain (At Month 3) ≥ 128 | 7 (3.41 to 11.11) | 2 (0.61 to 5.62) | 2 (0.22 to 6.30) | 1 (0.02 to 5.05) | 3 (0.89 to 8.12) | 3 (0.82 to 7.47) |
| M14459 Strain (At Month 7) ≥ LLQ (8.0) | 34 (26.91 to 41.02) | 30 (23.03 to 36.88) | 17 (10.53 to 25.22) | 86 (78.13 to 92.01) | 15 (9.56 to 23.07) | 89 (82.21 to 93.60) |
| M14459 Strain (At Month 7) ≥ 5 | 44 (36.73 to 51.51) | 35 (28.22 to 42.67) | 21 (14.24 to 30.19) | 92 (84.77 to 96.12) | 20 (12.92 to 27.63) | 93 (87.63 to 96.88) |
| M14459 Strain (At Month 7) ≥ 8 | 34 (26.91 to 41.02) | 30 (23.03 to 36.88) | 17 (10.53 to 25.22) | 86 (78.13 to 92.01) | 15 (9.56 to 23.07) | 89 (82.21 to 93.60) |
| M14459 Strain (At Month 7) ≥ 16 | 19 (13.62 to 25.45) | 14 (9.25 to 19.92) | 10 (5.01 to 16.89) | 69 (59.84 to 77.95) | 8 (3.97 to 14.44) | 72 (63.21 to 79.09) |
| M14459 Strain (At Month 7) ≥ 32 | 11 (7.21 to 16.92) | 7 (3.51 to 11.42) | 5 (1.99 to 11.30) | 50 (40.22 to 59.78) | 6 (2.32 to 11.37) | 49 (40.52 to 58.02) |
| M14459 Strain (At Month 7) ≥ 64 | 3 (1.21 to 6.96) | 4 (1.59 to 7.89) | 3 (0.56 to 7.63) | 23 (15.57 to 32.25) | 4 (1.33 to 9.23) | 22 (15.64 to 30.39) |
| M14459 Strain (At Month 7) ≥ 128 | 0 (0 to 1.98) | 1 (0.01 to 3.07) | 1 (0.02 to 4.87) | 10 (5.20 to 17.49) | 2 (0.20 to 5.75) | 7 (3.12 to 12.37) |
| M14459 Strain (At Month 13) ≥ LLQ (8.0) | 23 (17.46 to 30.16) | 20 (14.01 to 26.13) | 13 (7.01 to 20.08) | 23 (15.57 to 32.25) | 89 (81.64 to 93.64) | 27 (19.58 to 35.20) |
| M14459 Strain (At Month 13) ≥ 5 | 30 (23.88 to 37.63) | 26 (19.47 to 32.75) | 20 (12.74 to 28.22) | 37 (27.94 to 46.86) | 93 (86.56 to 96.60) | 38 (29.82 to 46.84) |
| M14459 Strain (At Month 13) ≥ 8 | 23 (17.46 to 30.16) | 20 (14.01 to 26.13) | 13 (7.01 to 20.08) | 23 (15.57 to 32.25) | 89 (81.64 to 93.64) | 27 (19.58 to 35.20) |
| M14459 Strain (At Month 13) ≥ 16 | 15 (9.90 to 20.63) | 9 (5.63 to 14.77) | 7 (3.13 to 13.59) | 13 (7.27 to 20.79) | 76 (67.05 to 82.90) | 13 (7.57 to 19.53) |
| M14459 Strain (At Month 13) ≥ 32 | 5 (2.64 to 9.77) | 4 (1.95 to 8.62) | 4 (0.98 to 8.89) | 7 (3.25 to 14.07) | 54 (45.25 to 63.47) | 6 (2.61 to 11.42) |
| M14459 Strain (At Month 13) ≥ 64 | 2 (0.34 to 4.69) | 2 (0.61 to 5.62) | 3 (0.56 to 7.63) | 1 (0.02 to 5.05) | 29 (21.41 to 38.15) | 1 (0.18 to 5.29) |
| M14459 Strain (At Month 13) ≥ 128 | 0 (0 to 1.98) | 1 (0.01 to 3.07) | 2 (0.22 to 6.30) | 1 (0.02 to 5.05) | 11 (5.75 to 17.40) | 1 (0.02 to 4.09) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M07-0241084 B strain was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| M07-0241084 Strain (At Month 0) ≥ LLQ (8.9) | 21 (15.19 to 27.25) | 18 (12.78 to 24.69) | 17 (10.77 to 25.16) | 14 (8.32 to 21.97) | 21 (14.54 to 29.88) | 19 (12.40 to 26.60) |
| M07-0241084 Strain (At Month 0) ≥ 5 | 30 (23.35 to 36.87) | 28 (21.36 to 35.08) | 25 (17.27 to 33.62) | 27 (19.46 to 36.63) | 30 (21.79 to 38.74) | 21 (14.38 to 29.19) |
| M07-0241084 Strain (At Month 0) ≥ 8 | 22 (16.13 to 28.40) | 20 (14.26 to 26.56) | 18 (11.47 to 26.12) | 19 (12.62 to 27.98) | 24 (16.68 to 32.57) | 20 (13.72 to 28.33) |
| M07-0241084 Strain (At Month 0) ≥ 16 | 13 (8.79 to 19.00) | 14 (9.41 to 20.25) | 12 (6.70 to 19.26) | 6 (2.53 to 12.35) | 16 (9.73 to 23.43) | 15 (9.18 to 22.21) |
| M07-0241084 Strain (At Month 0) ≥ 32 | 8 (4.53 to 12.82) | 6 (3.16 to 10.91) | 7 (3.00 to 13.03) | 4 (0.97 to 8.82) | 9 (4.63 to 15.68) | 6 (2.74 to 11.94) |
| M07-0241084 Strain (At Month 0) ≥ 64 | 3 (1.18 to 6.82) | 2 (0.35 to 4.90) | 3 (0.53 to 7.31) | 2 (0.22 to 6.25) | 3 (0.91 to 8.25) | 3 (0.86 to 7.81) |
| M07-0241084 Strain (At Month 0) ≥ 128 | 0 (0 to 1.94) | 0 (0 to 2.07) | 0 (0 to 3.10) | 2 (0.22 to 6.25) | 1 (0.02 to 4.52) | 1 (0.02 to 4.28) |
| M07-0241084 Strain (At Month 2) ≥ LLQ (8.9) | 38 (30.81 to 45.11) | 29 (22.40 to 36.28) | 37 (28.03 to 46.16) | 28 (20.24 to 37.57) | 39 (30.12 to 48.13) | 30 (22.65 to 39.22) |
| M07-0241084 Strain (At Month 2) ≥ 5 | 47 (40.03 to 54.74) | 43 (35.75 to 50.85) | 54 (44.39 to 63.10) | 40 (30.73 to 49.46) | 54 (44.43 to 62.83) | 41 (32.04 to 49.66) |
| M07-0241084 Strain (At Month 2) ≥ 8 | 42 (34.88 to 49.42) | 32 (25.54 to 39.84) | 43 (33.63 to 52.21) | 31 (22.61 to 40.36) | 43 (34.01 to 52.29) | 35 (26.93 to 44.09) |
| M07-0241084 Strain (At Month 2) ≥ 16 | 31 (24.33 to 37.98) | 22 (16.26 to 29.02) | 29 (21.04 to 38.17) | 16 (9.72 to 24.00) | 30 (21.79 to 38.74) | 19 (12.40 to 26.60) |
| M07-0241084 Strain (At Month 2) ≥ 32 | 20 (14.72 to 26.67) | 15 (10.36 to 21.53) | 17 (10.77 to 25.16) | 7 (3.11 to 13.47) | 19 (12.45 to 27.14) | 9 (4.37 to 14.86) |
| M07-0241084 Strain (At Month 2) ≥ 64 | 10 (5.77 to 14.71) | 7 (3.99 to 12.30) | 9 (4.17 to 15.16) | 2 (0.22 to 6.25) | 9 (4.63 to 15.68) | 5 (1.74 to 9.92) |
| M07-0241084 Strain (At Month 2) ≥ 128 | 3 (1.18 to 6.82) | 2 (0.35 to 4.90) | 3 (0.53 to 7.31) | 1 (0.02 to 4.83) | 5 (1.84 to 10.48) | 0 (0 to 2.84) |
| M07-0241084 Strain (At Month 3) ≥ LLQ (8.9) | 66 (59.26 to 73.19) | 47 (39.60 to 54.81) | 28 (20.28 to 37.27) | 28 (20.24 to 37.57) | 30 (21.79 to 38.74) | 53 (44.11 to 62.00) |
| M07-0241084 Strain (At Month 3) ≥ 5 | 79 (72.75 to 84.81) | 69 (61.94 to 76.04) | 43 (33.63 to 52.21) | 40 (30.73 to 49.46) | 43 (34.01 to 52.29) | 62 (52.72 to 70.17) |
| M07-0241084 Strain (At Month 3) ≥ 8 | 69 (62.02 to 75.67) | 55 (47.45 to 62.60) | 34 (25.67 to 43.53) | 31 (22.61 to 40.36) | 34 (25.53 to 43.05) | 56 (47.21 to 65.00) |
| M07-0241084 Strain (At Month 3) ≥ 16 | 52 (44.74 to 59.45) | 33 (26.07 to 40.43) | 21 (14.33 to 29.91) | 12 (6.27 to 18.87) | 21 (14.54 to 29.88) | 40 (31.30 to 48.87) |
| M07-0241084 Strain (At Month 3) ≥ 32 | 33 (26.31 to 40.19) | 18 (12.78 to 24.69) | 15 (9.38 to 23.22) | 5 (1.97 to 11.20) | 15 (9.06 to 22.49) | 23 (15.73 to 30.89) |
| M07-0241084 Strain (At Month 3) ≥ 64 | 18 (12.40 to 23.76) | 11 (7.08 to 17.00) | 5 (1.90 to 10.83) | 1 (0.02 to 4.83) | 4 (1.36 to 9.38) | 13 (7.32 to 19.50) |
| M07-0241084 Strain (At Month 3) ≥ 128 | 5 (2.21 to 8.89) | 3 (0.93 to 6.50) | 3 (0.53 to 7.31) | 1 (0.02 to 4.83) | 2 (0.51 to 7.07) | 2 (0.49 to 6.70) |
| M07-0241084 Strain (At Month 7) ≥ LLQ (8.9) | 40 (32.84 to 47.27) | 30 (22.92 to 36.88) | 26 (18.02 to 34.54) | 66 (56.88 to 74.99) | 26 (18.12 to 34.35) | 70 (61.60 to 78.06) |
| M07-0241084 Strain (At Month 7) ≥ 5 | 50 (42.64 to 57.36) | 44 (36.30 to 51.42) | 32 (24.11 to 41.76) | 83 (74.99 to 89.56) | 36 (27.81 to 45.60) | 80 (72.53 to 86.94) |
| M07-0241084 Strain (At Month 7) ≥ 8 | 42 (34.88 to 49.42) | 32 (25.54 to 39.84) | 27 (19.52 to 36.36) | 70 (60.57 to 78.18) | 28 (20.31 to 36.99) | 77 (68.26 to 83.59) |
| M07-0241084 Strain (At Month 7) ≥ 16 | 29 (22.37 to 35.76) | 24 (18.28 to 31.47) | 19 (12.18 to 27.07) | 53 (43.48 to 62.55) | 18 (11.76 to 26.22) | 58 (48.77 to 66.49) |
| M07-0241084 Strain (At Month 7) ≥ 32 | 21 (15.19 to 27.25) | 14 (8.94 to 19.61) | 9 (4.79 to 16.20) | 28 (20.24 to 37.57) | 8 (4.03 to 14.67) | 34 (25.49 to 42.48) |
| M07-0241084 Strain (At Month 7) ≥ 64 | 6 (2.96 to 10.23) | 8 (4.42 to 12.99) | 6 (2.44 to 11.94) | 10 (4.96 to 16.75) | 4 (1.36 to 9.38) | 17 (11.10 to 24.86) |
| M07-0241084 Strain (At Month 7) ≥ 128 | 1 (0.01 to 2.93) | 2 (0.35 to 4.90) | 1 (0.02 to 4.67) | 3 (0.55 to 7.56) | 1 (0.02 to 4.52) | 4 (1.28 to 8.88) |
| M07-0241084 Strain (At Month 13) ≥ LLQ (8.9) | 34 (26.81 to 40.74) | 27 (20.84 to 34.48) | 23 (15.79 to 31.77) | 34 (25.01 to 43.12) | 69 (59.53 to 76.73) | 37 (28.38 to 45.69) |
| M07-0241084 Strain (At Month 13) ≥ 5 | 46 (38.48 to 53.15) | 39 (31.95 to 46.83) | 36 (27.24 to 45.29) | 57 (46.99 to 65.93) | 82 (73.78 to 88.24) | 51 (41.80 to 59.72) |
| M07-0241084 Strain (At Month 13) ≥ 8 | 37 (29.81 to 44.02) | 34 (26.60 to 41.01) | 27 (19.52 to 36.36) | 39 (29.91 to 48.56) | 74 (64.76 to 81.16) | 42 (33.51 to 51.23) |
| M07-0241084 Strain (At Month 13) ≥ 16 | 26 (19.46 to 32.39) | 23 (16.76 to 29.64) | 17 (10.77 to 25.16) | 19 (12.62 to 27.98) | 55 (45.24 to 63.62) | 26 (18.46 to 34.26) |
| M07-0241084 Strain (At Month 13) ≥ 32 | 16 (11.03 to 21.99) | 13 (8.47 to 18.96) | 11 (6.05 to 18.25) | 12 (6.27 to 18.87) | 35 (26.29 to 43.90) | 12 (6.71 to 18.59) |
| M07-0241084 Strain (At Month 13) ≥ 64 | 6 (3.34 to 10.88) | 3 (1.26 to 7.27) | 4 (1.40 to 9.69) | 5 (1.97 to 11.20) | 20 (13.14 to 28.06) | 5 (1.74 to 9.92) |
| M07-0241084 Strain (At Month 13) ≥ 128 | 2 (0.58 to 5.36) | 1 (0.01 to 3.12) | 2 (0.21 to 6.04) | 1 (0.02 to 4.83) | 9 (4.63 to 15.68) | 1 (0.02 to 4.28) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against 96217 B strain was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| 96217 Strain (At Month 0) ≥ LLQ (8.6) | 23 (17.26 to 29.85) | 29 (22.14 to 35.89) | 29 (21.23 to 38.16) | 28 (19.64 to 36.93) | 25 (17.77 to 33.42) | 27 (19.57 to 36.12) |
| 96217 Strain (At Month 0) ≥ 5 | 26 (19.68 to 32.72) | 35 (28.38 to 42.90) | 35 (26.52 to 44.24) | 29 (21.23 to 38.82) | 35 (26.93 to 44.09) | 29 (21.05 to 37.87) |
| 96217 Strain (At Month 0) ≥ 8 | 24 (18.23 to 31.00) | 30 (23.68 to 37.66) | 31 (22.73 to 39.91) | 28 (19.64 to 36.93) | 25 (17.77 to 33.42) | 27 (19.57 to 36.12) |
| 96217 Strain (At Month 0) ≥ 16 | 16 (11.15 to 22.22) | 17 (11.67 to 23.18) | 22 (14.67 to 30.11) | 19 (12.00 to 27.22) | 18 (11.74 to 25.73) | 16 (9.73 to 23.43) |
| 96217 Strain (At Month 0) ≥ 32 | 6 (3.38 to 11.00) | 8 (4.37 to 12.84) | 8 (4.07 to 14.79) | 4 (1.47 to 10.11) | 8 (3.81 to 13.90) | 7 (2.90 to 12.61) |
| 96217 Strain (At Month 0) ≥ 64 | 2 (0.33 to 4.64) | 2 (0.62 to 5.65) | 3 (0.52 to 7.13) | 0 (0 to 3.24) | 2 (0.49 to 6.70) | 5 (1.84 to 10.48) |
| 96217 Strain (At Month 0) ≥ 128 | 1 (0.01 to 2.96) | 1 (0.14 to 4.00) | 0 (0 to 3.03) | 0 (0 to 3.24) | 1 (0.02 to 4.28) | 2 (0.20 to 5.84) |
| 96217 Strain (At Month 2) ≥ LLQ (8.6) | 69 (61.63 to 75.39) | 64 (56.53 to 71.09) | 97 (91.69 to 99.08) | 62 (51.94 to 70.64) | 58 (48.77 to 66.49) | 50 (40.37 to 58.82) |
| 96217 Strain (At Month 2) ≥ 5 | 75 (68.42 to 81.29) | 67 (60.00 to 74.24) | 97 (91.69 to 99.08) | 66 (56.52 to 74.75) | 66 (56.72 to 73.79) | 53 (43.61 to 62.03) |
| 96217 Strain (At Month 2) ≥ 8 | 70 (63.31 to 76.88) | 64 (56.53 to 71.09) | 97 (91.69 to 99.08) | 63 (53.76 to 72.29) | 59 (50.34 to 67.96) | 51 (41.99 to 60.43) |
| 96217 Strain (At Month 2) ≥ 16 | 48 (41.01 to 55.81) | 48 (40.78 to 55.91) | 94 (88.35 to 97.62) | 48 (38.67 to 57.85) | 42 (33.51 to 51.23) | 39 (30.12 to 48.13) |
| 96217 Strain (At Month 2) ≥ 32 | 27 (21.15 to 34.43) | 21 (15.57 to 28.10) | 84 (76.38 to 90.19) | 20 (12.74 to 28.22) | 26 (18.46 to 34.26) | 24 (16.68 to 32.57) |
| 96217 Strain (At Month 2) ≥ 64 | 11 (6.69 to 16.12) | 15 (9.77 to 20.67) | 73 (63.60 to 80.25) | 9 (4.36 to 15.81) | 14 (8.55 to 21.31) | 12 (6.47 to 18.65) |
| 96217 Strain (At Month 2) ≥ 128 | 7 (3.77 to 11.66) | 4 (1.96 to 8.66) | 45 (35.91 to 54.35) | 4 (1.47 to 10.11) | 9 (4.94 to 15.80) | 7 (3.46 to 13.65) |
| 96217 Strain (At Month 3) ≥ LLQ (8.6) | 99 (97.04 to 99.99) | 97 (92.81 to 98.75) | 94 (88.35 to 97.62) | 58 (48.34 to 67.30) | 47 (38.00 to 55.89) | 97 (91.75 to 99.09) |
| 96217 Strain (At Month 3) ≥ 5 | 99 (97.04 to 99.99) | 97 (93.57 to 99.08) | 96 (90.54 to 98.53) | 61 (51.04 to 69.81) | 56 (47.21 to 65.00) | 98 (92.93 to 99.49) |
| 96217 Strain (At Month 3) ≥ 8 | 99 (97.04 to 99.99) | 97 (92.81 to 98.75) | 95 (89.43 to 98.14) | 58 (48.34 to 67.30) | 52 (43.34 to 61.24) | 97 (91.75 to 99.09) |
| 96217 Strain (At Month 3) ≥ 16 | 99 (97.04 to 99.99) | 95 (90.62 to 97.66) | 91 (84.19 to 95.33) | 40 (31.03 to 49.86) | 36 (27.65 to 44.89) | 95 (89.52 to 98.16) |
| 96217 Strain (At Month 3) ≥ 32 | 98 (95.36 to 99.67) | 89 (83.83 to 93.45) | 83 (75.44 to 89.51) | 21 (13.49 to 29.20) | 23 (15.73 to 30.89) | 92 (85.33 to 95.97) |
| 96217 Strain (At Month 3) ≥ 64 | 90 (84.51 to 93.74) | 81 (74.34 to 86.39) | 62 (52.35 to 70.39) | 6 (2.55 to 12.45) | 11 (6.11 to 17.67) | 84 (76.57 to 90.27) |
| 96217 Strain (At Month 3) ≥ 128 | 74 (67.28 to 80.32) | 63 (55.38 to 70.03) | 34 (25.76 to 43.38) | 4 (1.47 to 10.11) | 4 (1.28 to 8.88) | 60 (51.04 to 69.11) |
| 96217 Strain (At Month 7) ≥ LLQ (8.6) | 95 (91.01 to 97.76) | 91 (85.81 to 94.77) | 88 (80.22 to 92.83) | 97 (92.37 to 99.44) | 39 (30.56 to 48.08) | 99 (95.48 to 99.98) |
| 96217 Strain (At Month 7) ≥ 5 | 96 (92.40 to 98.47) | 93 (87.83 to 96.05) | 91 (84.19 to 95.33) | 97 (92.37 to 99.44) | 44 (35.00 to 52.79) | 99 (95.48 to 99.98) |
| 96217 Strain (At Month 7) ≥ 8 | 95 (91.01 to 97.76) | 91 (85.81 to 94.77) | 88 (80.22 to 92.83) | 97 (92.37 to 99.44) | 40 (31.30 to 48.87) | 99 (95.48 to 99.98) |
| 96217 Strain (At Month 7) ≥ 16 | 93 (88.34 to 96.23) | 85 (79.33 to 90.23) | 76 (67.17 to 83.18) | 96 (91.11 to 99.02) | 30 (22.65 to 39.22) | 99 (95.48 to 99.98) |
| 96217 Strain (At Month 7) ≥ 32 | 75 (67.85 to 80.80) | 65 (57.68 to 72.14) | 57 (47.31 to 65.68) | 96 (89.89 to 98.53) | 18 (11.74 to 25.73) | 98 (94.16 to 99.80) |
| 96217 Strain (At Month 7) ≥ 64 | 43 (35.79 to 50.46) | 34 (26.81 to 41.16) | 32 (23.48 to 40.78) | 87 (78.87 to 92.31) | 7 (3.27 to 12.93) | 98 (92.93 to 99.49) |
| 96217 Strain (At Month 7) ≥ 128 | 11 (7.13 to 16.74) | 7 (3.53 to 11.48) | 12 (6.53 to 18.80) | 73 (64.02 to 81.14) | 2 (0.49 to 6.70) | 85 (77.51 to 90.94) |
| 96217 Strain (At Month 13) ≥ LLQ (8.6) | 87 (81.41 to 91.55) | 83 (76.20 to 87.85) | 81 (72.64 to 87.44) | 90 (83.11 to 94.99) | 98 (93.30 to 99.51) | 93 (87.39 to 97.10) |
| 96217 Strain (At Month 13) ≥ 5 | 90 (85.14 to 94.16) | 85 (78.70 to 89.76) | 83 (75.44 to 89.51) | 92 (85.29 to 96.26) | 98 (94.47 to 99.81) | 93 (87.39 to 97.10) |
| 96217 Strain (At Month 13) ≥ 8 | 88 (82.03 to 92.00) | 83 (76.82 to 88.33) | 81 (72.64 to 87.44) | 90 (83.11 to 94.99) | 98 (94.47 to 99.81) | 93 (87.39 to 97.10) |
| 96217 Strain (At Month 13) ≥ 16 | 76 (69.00 to 81.77) | 69 (61.75 to 75.80) | 66 (56.62 to 74.24) | 79 (70.80 to 86.51) | 98 (93.30 to 99.51) | 88 (80.38 to 92.89) |
| 96217 Strain (At Month 13) ≥ 32 | 52 (44.72 to 59.51) | 40 (32.64 to 47.48) | 41 (31.95 to 50.18) | 57 (47.45 to 66.45) | 96 (91.12 to 98.72) | 64 (55.25 to 72.95) |
| 96217 Strain (At Month 13) ≥ 64 | 23 (17.26 to 29.85) | 13 (8.37 to 18.76) | 23 (15.38 to 31.02) | 30 (22.02 to 39.76) | 85 (77.79 to 90.82) | 36 (27.81 to 45.60) |
| 96217 Strain (At Month 13) ≥ 128 | 4 (1.87 to 8.30) | 3 (0.92 to 6.43) | 8 (3.49 to 13.76) | 13 (7.69 to 21.13) | 73 (64.08 to 80.16) | 12 (7.11 to 19.62) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against A human serogroup was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| A human Serogroup (At Month 0) ≥ LLQ (22.7) | 6 (2.82 to 10.43) | 3 (1.25 to 7.19) | 5 (1.53 to 10.57) | 2 (0.23 to 6.71) | 3 (0.52 to 7.13) | 1 (0.02 to 4.31) |
| A human Serogroup (At Month 0) ≥ 5 | 10 (6.32 to 16.03) | 6 (3.12 to 10.79) | 10 (5.24 to 17.65) | 4 (1.05 to 9.47) | 8 (3.49 to 13.76) | 3 (0.86 to 7.87) |
| A human Serogroup (At Month 0) ≥ 8 | 10 (5.86 to 15.35) | 6 (2.73 to 10.09) | 10 (5.24 to 17.65) | 3 (0.59 to 8.12) | 5 (1.86 to 10.57) | 2 (0.49 to 6.75) |
| A human Serogroup (At Month 0) ≥ 16 | 7 (3.66 to 11.87) | 4 (1.96 to 8.66) | 7 (3.28 to 14.20) | 2 (0.23 to 6.71) | 4 (1.37 to 9.46) | 2 (0.19 to 5.57) |
| A human Serogroup (At Month 0) ≥ 32 | 4 (1.65 to 8.21) | 2 (0.62 to 5.65) | 3 (0.58 to 7.98) | 1 (0.02 to 5.19) | 2 (0.20 to 5.89) | 1 (0.02 to 4.31) |
| A human Serogroup (At Month 0) ≥ 64 | 1 (0.14 to 4.14) | 1 (0.14 to 4.00) | 2 (0.23 to 6.59) | 1 (0.02 to 5.19) | 0 (0 to 3.03) | 1 (0.02 to 4.31) |
| A human Serogroup (At Month 0) ≥ 128 | 1 (0.01 to 3.20) | 1 (0.01 to 3.09) | 1 (0.02 to 5.10) | 0 (0 to 3.45) | 0 (0 to 3.03) | 1 (0.02 to 4.31) |
| A human Serogroup (At Month 2) ≥ LLQ (22.7) | 22 (16.13 to 29.04) | 35 (27.86 to 42.32) | 93 (85.80 to 96.72) | 33 (24.43 to 43.20) | 54 (44.83 to 63.29) | 28 (20.01 to 36.19) |
| A human Serogroup (At Month 2) ≥ 5 | 37 (29.97 to 44.89) | 53 (45.76 to 60.87) | 95 (89.43 to 98.47) | 48 (37.78 to 57.59) | 75 (66.27 to 82.45) | 39 (30.08 to 47.63) |
| A human Serogroup (At Month 2) ≥ 8 | 37 (29.43 to 44.30) | 51 (42.98 to 58.12) | 94 (88.19 to 97.91) | 46 (35.96 to 55.72) | 74 (65.38 to 81.72) | 38 (29.35 to 46.83) |
| A human Serogroup (At Month 2) ≥ 16 | 28 (21.35 to 35.24) | 44 (36.41 to 51.44) | 93 (86.98 to 97.33) | 41 (31.45 to 50.98) | 67 (57.48 to 75.01) | 31 (22.83 to 39.51) |
| A human Serogroup (At Month 2) ≥ 32 | 19 (13.09 to 25.24) | 33 (26.28 to 40.58) | 88 (80.12 to 93.37) | 30 (21.02 to 39.22) | 42 (32.74 to 51.02) | 22 (15.18 to 30.26) |
| A human Serogroup (At Month 2) ≥ 64 | 12 (7.72 to 18.06) | 19 (13.12 to 25.04) | 69 (59.50 to 77.73) | 18 (11.26 to 26.81) | 33 (24.23 to 41.65) | 14 (8.62 to 21.47) |
| A human Serogroup (At Month 2) ≥ 128 | 4 (1.65 to 8.21) | 10 (5.66 to 14.85) | 34 (24.80 to 43.42) | 9 (3.99 to 15.65) | 14 (8.47 to 21.71) | 6 (2.76 to 12.03) |
| A human Serogroup (At Month 3) ≥ LLQ (22.7) | 94 (89.57 to 97.18) | 87 (80.61 to 91.17) | 80 (71.58 to 87.42) | 30 (21.02 to 39.22) | 38 (28.83 to 46.80) | 92 (86.00 to 96.16) |
| A human Serogroup (At Month 3) ≥ 5 | 97 (93.35 to 99.05) | 94 (89.21 to 96.88) | 92 (84.63 to 96.08) | 40 (30.56 to 50.02) | 55 (45.65 to 64.09) | 94 (88.97 to 97.76) |
| A human Serogroup (At Month 3) ≥ 8 | 97 (93.35 to 99.05) | 93 (87.83 to 96.05) | 91 (83.48 to 95.43) | 39 (29.67 to 49.06) | 53 (43.18 to 61.69) | 94 (87.97 to 97.24) |
| A human Serogroup (At Month 3) ≥ 16 | 95 (90.30 to 97.58) | 91 (85.81 to 94.77) | 86 (77.93 to 91.94) | 33 (24.43 to 43.20) | 42 (32.74 to 51.02) | 92 (86.00 to 96.16) |
| A human Serogroup (At Month 3) ≥ 32 | 91 (85.33 to 94.59) | 83 (76.20 to 87.85) | 74 (64.45 to 81.85) | 27 (18.51 to 36.19) | 31 (22.73 to 39.91) | 90 (83.13 to 94.44) |
| A human Serogroup (At Month 3) ≥ 64 | 71 (63.53 to 77.59) | 57 (49.69 to 64.67) | 46 (36.12 to 55.70) | 12 (6.76 to 20.24) | 19 (12.56 to 27.36) | 61 (51.57 to 69.18) |
| A human Serogroup (At Month 3) ≥ 128 | 45 (37.76 to 53.10) | 30 (23.17 to 37.07) | 21 (14.14 to 30.49) | 6 (2.13 to 12.02) | 10 (5.27 to 16.82) | 29 (21.41 to 37.85) |
| A human Serogroup (At Month 7) ≥ LLQ (22.7) | 53 (45.74 to 61.12) | 46 (38.04 to 53.12) | 41 (31.70 to 51.05) | 95 (89.24 to 98.44) | 21 (13.96 to 29.20) | 94 (87.97 to 97.24) |
| A human Serogroup (At Month 7) ≥ 5 | 70 (62.31 to 76.53) | 62 (54.80 to 69.50) | 60 (49.89 to 69.18) | 97 (91.88 to 99.41) | 29 (21.23 to 38.16) | 98 (93.25 to 99.51) |
| A human Serogroup (At Month 7) ≥ 8 | 68 (60.50 to 74.92) | 58 (50.82 to 65.75) | 58 (48.01 to 67.42) | 97 (91.88 to 99.41) | 28 (19.75 to 36.40) | 98 (93.25 to 99.51) |
| A human Serogroup (At Month 7) ≥ 16 | 61 (53.33 to 68.38) | 51 (43.53 to 58.67) | 49 (38.82 to 58.46) | 97 (91.88 to 99.41) | 22 (14.67 to 30.11) | 97 (92.13 to 99.14) |
| A human Serogroup (At Month 7) ≥ 32 | 42 (34.95 to 50.20) | 37 (29.44 to 44.05) | 35 (25.65 to 44.39) | 91 (84.35 to 96.01) | 14 (8.47 to 21.71) | 93 (86.97 to 96.71) |
| A human Serogroup (At Month 7) ≥ 64 | 19 (13.59 to 25.88) | 19 (13.61 to 25.66) | 18 (11.04 to 26.33) | 76 (66.89 to 83.96) | 7 (2.92 to 12.71) | 80 (72.33 to 86.84) |
| A human Serogroup (At Month 7) ≥ 128 | 5 (2.42 to 9.70) | 6 (2.73 to 10.09) | 10 (5.24 to 17.65) | 63 (52.88 to 72.09) | 3 (0.52 to 7.13) | 54 (44.48 to 62.44) |
| A human Serogroup (At Month 13) ≥ LLQ (22.7) | 33 (26.16 to 40.71) | 26 (20.09 to 33.52) | 34 (24.80 to 43.42) | 51 (41.47 to 61.30) | 93 (87.29 to 97.08) | 54 (45.26 to 63.19) |
| A human Serogroup (At Month 13) ≥ 5 | 51 (42.87 to 58.28) | 42 (34.25 to 49.18) | 48 (37.92 to 57.54) | 68 (57.79 to 76.43) | 98 (92.87 to 99.48) | 65 (55.59 to 72.85) |
| A human Serogroup (At Month 13) ≥ 8 | 48 (40.59 to 55.99) | 39 (31.57 to 46.34) | 47 (37.02 to 56.62) | 66 (55.81 to 74.70) | 98 (92.87 to 99.48) | 64 (54.78 to 72.12) |
| A human Serogroup (At Month 13) ≥ 16 | 38 (30.52 to 45.49) | 30 (23.68 to 37.66) | 41 (31.70 to 51.05) | 59 (49.02 to 68.55) | 95 (89.43 to 98.14) | 60 (50.78 to 68.44) |
| A human Serogroup (At Month 13) ≥ 32 | 24 (17.68 to 30.92) | 20 (14.09 to 26.27) | 27 (18.96 to 36.55) | 44 (34.14 to 53.83) | 88 (81.20 to 93.47) | 41 (32.30 to 50.02) |
| A human Serogroup (At Month 13) ≥ 64 | 13 (8.67 to 19.39) | 8 (4.79 to 13.52) | 13 (7.34 to 20.98) | 27 (18.51 to 36.19) | 81 (72.64 to 87.44) | 16 (9.89 to 23.27) |
| A human Serogroup (At Month 13) ≥ 128 | 4 (1.65 to 8.21) | 2 (0.35 to 4.85) | 6 (2.09 to 11.81) | 8 (3.35 to 14.46) | 61 (51.50 to 69.61) | 6 (2.24 to 11.03) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against C human serogroup was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| C human Serogroup (At Month 0) ≥ LLQ (5.2) | 43 (35.79 to 50.46) | 45 (38.09 to 52.87) | 48 (38.43 to 56.78) | 41 (32.09 to 50.83) | 48 (38.88 to 57.16) | 41 (32.24 to 49.73) |
| C human Serogroup (At Month 0) ≥ 5 | 46 (38.91 to 53.68) | 45 (38.09 to 52.87) | 49 (40.02 to 58.38) | 43 (33.75 to 52.59) | 49 (39.67 to 57.95) | 42 (32.97 to 50.51) |
| C human Serogroup (At Month 0) ≥ 8 | 34 (27.61 to 41.71) | 30 (23.75 to 37.44) | 36 (27.57 to 45.25) | 30 (21.62 to 39.11) | 36 (27.33 to 44.91) | 30 (22.28 to 38.66) |
| C human Serogroup (At Month 0) ≥ 16 | 19 (13.47 to 25.19) | 14 (8.94 to 19.30) | 20 (13.03 to 27.84) | 14 (8.24 to 21.79) | 24 (17.10 to 32.95) | 8 (3.75 to 13.69) |
| C human Serogroup (At Month 0) ≥ 32 | 5 (2.61 to 9.66) | 6 (3.40 to 11.06) | 9 (4.59 to 15.56) | 4 (0.96 to 8.74) | 7 (3.40 to 13.44) | 3 (0.84 to 7.69) |
| C human Serogroup (At Month 0) ≥ 64 | 2 (0.59 to 5.41) | 2 (0.34 to 4.67) | 2 (0.20 to 5.80) | 3 (0.55 to 7.50) | 3 (0.89 to 8.12) | 1 (0.02 to 4.21) |
| C human Serogroup (At Month 0) ≥ 128 | 1 (0.01 to 2.96) | 2 (0.34 to 4.67) | 0 (0 to 2.98) | 1 (0.02 to 4.79) | 1 (0.02 to 4.45) | 0 (0 to 2.80) |
| C human Serogroup (At Month 2) ≥ LLQ (5.2) | 61 (53.89 to 68.33) | 84 (78.27 to 89.24) | 100 (97.02 to 100) | 84 (76.20 to 90.37) | 89 (82.60 to 94.25) | 88 (80.78 to 92.80) |
| C human Serogroup (At Month 2) ≥ 5 | 62 (54.98 to 69.35) | 84 (78.27 to 89.24) | 100 (97.02 to 100) | 84 (76.20 to 90.37) | 89 (82.60 to 94.25) | 88 (80.78 to 92.80) |
| C human Serogroup (At Month 2) ≥ 8 | 53 (45.25 to 60.04) | 78 (71.16 to 83.60) | 98 (94.20 to 99.80) | 80 (71.28 to 86.76) | 86 (78.80 to 91.74) | 78 (69.56 to 84.52) |
| C human Serogroup (At Month 2) ≥ 16 | 35 (28.62 to 42.82) | 65 (57.52 to 71.73) | 95 (89.60 to 98.17) | 64 (54.51 to 72.81) | 72 (62.71 to 79.31) | 61 (51.82 to 69.21) |
| C human Serogroup (At Month 2) ≥ 32 | 18 (13.00 to 24.60) | 40 (32.88 to 47.44) | 89 (81.50 to 93.58) | 44 (34.58 to 53.46) | 55 (46.06 to 64.25) | 44 (35.16 to 52.82) |
| C human Serogroup (At Month 2) ≥ 64 | 8 (4.58 to 12.95) | 23 (17.36 to 30.00) | 79 (70.35 to 85.58) | 29 (20.84 to 38.19) | 39 (30.36 to 48.23) | 25 (17.49 to 32.94) |
| C human Serogroup (At Month 2) ≥ 128 | 3 (0.88 to 6.16) | 16 (10.76 to 21.73) | 53 (44.03 to 62.36) | 17 (10.34 to 24.80) | 26 (18.52 to 34.70) | 19 (12.85 to 27.07) |
| C human Serogroup (At Month 3) ≥ LLQ (5.2) | 97 (93.84 to 99.12) | 99 (96.15 to 99.87) | 98 (94.20 to 99.80) | 81 (72.25 to 87.49) | 88 (80.68 to 93.01) | 99 (95.79 to 99.98) |
| C human Serogroup (At Month 3) ≥ 5 | 97 (93.84 to 99.12) | 99 (96.15 to 99.87) | 98 (94.20 to 99.80) | 81 (72.25 to 87.49) | 88 (80.68 to 93.01) | 100 (97.20 to 100) |
| C human Serogroup (At Month 3) ≥ 8 | 94 (89.00 to 96.62) | 98 (94.56 to 99.41) | 98 (92.98 to 99.49) | 77 (68.40 to 84.53) | 84 (76.01 to 89.78) | 99 (95.79 to 99.98) |
| C human Serogroup (At Month 3) ≥ 16 | 78 (71.89 to 84.17) | 96 (92.36 to 98.47) | 95 (89.60 to 98.17) | 62 (52.72 to 71.19) | 63 (54.25 to 71.91) | 98 (93.40 to 99.52) |
| C human Serogroup (At Month 3) ≥ 32 | 56 (48.46 to 63.17) | 90 (84.43 to 93.70) | 86 (78.63 to 91.67) | 43 (33.75 to 52.59) | 46 (36.53 to 54.75) | 94 (88.23 to 97.31) |
| C human Serogroup (At Month 3) ≥ 64 | 26 (19.68 to 32.72) | 78 (71.16 to 83.60) | 67 (58.13 to 75.44) | 25 (17.75 to 34.45) | 30 (22.14 to 39.00) | 85 (77.24 to 90.34) |
| C human Serogroup (At Month 3) ≥ 128 | 11 (6.69 to 16.12) | 58 (50.92 to 65.57) | 40 (31.39 to 49.42) | 18 (11.06 to 25.79) | 21 (14.30 to 29.42) | 60 (51.05 to 68.49) |
| C human Serogroup (At Month 7) ≥ LLQ (5.2) | 69 (61.63 to 75.39) | 96 (92.36 to 98.47) | 97 (91.82 to 99.10) | 99 (95.21 to 99.98) | 82 (74.18 to 88.44) | 100 (97.20 to 100) |
| C human Serogroup (At Month 7) ≥ 5 | 69 (62.19 to 75.89) | 96 (92.36 to 98.47) | 97 (91.82 to 99.10) | 99 (95.21 to 99.98) | 82 (74.18 to 88.44) | 100 (97.20 to 100) |
| C human Serogroup (At Month 7) ≥ 8 | 58 (50.62 to 65.24) | 96 (92.36 to 98.47) | 96 (90.69 to 98.66) | 99 (95.21 to 99.98) | 73 (64.43 to 80.76) | 99 (95.79 to 99.98) |
| C human Serogroup (At Month 7) ≥ 16 | 38 (30.65 to 45.02) | 90 (85.06 to 94.13) | 91 (84.44 to 95.41) | 98 (93.81 to 99.79) | 55 (46.06 to 64.25) | 99 (95.79 to 99.98) |
| C human Serogroup (At Month 7) ≥ 32 | 23 (16.79 to 29.27) | 74 (66.54 to 79.72) | 77 (68.57 to 84.18) | 95 (88.90 to 98.04) | 35 (26.58 to 44.08) | 98 (94.55 to 99.81) |
| C human Serogroup (At Month 7) ≥ 64 | 9 (5.00 to 13.59) | 53 (45.51 to 60.34) | 53 (44.03 to 62.36) | 86 (78.21 to 91.76) | 26 (18.52 to 34.70) | 96 (91.25 to 98.74) |
| C human Serogroup (At Month 7) ≥ 128 | 3 (0.88 to 6.16) | 30 (23.75 to 37.44) | 25 (17.96 to 34.09) | 74 (64.61 to 81.49) | 16 (10.22 to 23.99) | 85 (78.12 to 90.97) |
| C human Serogroup (At Month 13) ≥ LLQ (5.2) | 60 (52.25 to 66.79) | 92 (87.63 to 95.80) | 94 (88.54 to 97.66) | 97 (92.50 to 99.45) | 100 (97.05 to 100) | 99 (95.79 to 99.98) |
| C human Serogroup (At Month 13) ≥ 5 | 61 (53.34 to 67.82) | 92 (87.63 to 95.80) | 94 (88.54 to 97.66) | 98 (93.81 to 99.79) | 100 (97.05 to 100) | 99 (95.79 to 99.98) |
| C human Serogroup (At Month 13) ≥ 8 | 48 (41.01 to 55.81) | 88 (82.55 to 92.40) | 89 (82.47 to 94.20) | 91 (84.46 to 95.71) | 98 (94.25 to 99.80) | 98 (93.40 to 99.52) |
| C human Serogroup (At Month 13) ≥ 16 | 30 (23.61 to 37.25) | 78 (71.26 to 83.60) | 79 (70.35 to 85.58) | 83 (75.20 to 89.66) | 98 (93.04 to 99.49) | 94 (88.23 to 97.31) |
| C human Serogroup (At Month 13) ≥ 32 | 15 (10.24 to 21.02) | 51 (43.37 to 58.22) | 57 (48.10 to 66.28) | 61 (51.83 to 70.37) | 97 (91.88 to 99.11) | 81 (72.93 to 87.15) |
| C human Serogroup (At Month 13) ≥ 64 | 9 (5.00 to 13.59) | 28 (21.76 to 35.17) | 25 (17.25 to 33.21) | 38 (28.81 to 47.28) | 93 (87.59 to 97.15) | 58 (49.49 to 67.03) |
| C human Serogroup (At Month 13) ≥ 128 | 2 (0.59 to 5.41) | 16 (10.76 to 21.73) | 16 (10.31 to 24.18) | 25 (16.98 to 33.51) | 85 (76.93 to 90.44) | 40 (31.51 to 48.95) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against W human serogroup was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| W human Serogroup (At Month 0) ≥ LLQ (39.6) | 30 (23.29 to 37.95) | 26 (19.86 to 33.17) | 29 (21.42 to 38.46) | 20 (13.23 to 29.20) | 29 (21.41 to 38.15) | 22 (14.99 to 30.31) |
| W human Serogroup (At Month 0) ≥ 5 | 51 (43.27 to 59.15) | 43 (35.98 to 50.91) | 41 (32.24 to 50.57) | 42 (32.25 to 51.55) | 45 (35.75 to 53.94) | 45 (35.75 to 53.94) |
| W human Serogroup (At Month 0) ≥ 8 | 49 (41.45 to 57.34) | 41 (33.85 to 48.67) | 40 (31.45 to 49.72) | 41 (31.38 to 50.62) | 45 (35.75 to 53.94) | 43 (34.20 to 52.32) |
| W human Serogroup (At Month 0) ≥ 16 | 44 (36.05 to 51.83) | 39 (31.73 to 46.42) | 39 (30.66 to 48.87) | 34 (25.40 to 44.01) | 41 (31.89 to 49.88) | 38 (29.60 to 47.41) |
| W human Serogroup (At Month 0) ≥ 32 | 35 (27.86 to 43.07) | 31 (24.43 to 38.42) | 31 (22.93 to 40.23) | 24 (16.37 to 33.25) | 33 (25.09 to 42.40) | 26 (18.52 to 34.70) |
| W human Serogroup (At Month 0) ≥ 64 | 21 (14.99 to 28.07) | 19 (13.45 to 25.38) | 20 (13.37 to 28.51) | 13 (7.27 to 20.79) | 21 (14.30 to 29.42) | 12 (6.99 to 19.32) |
| W human Serogroup (At Month 0) ≥ 128 | 8 (4.34 to 13.33) | 9 (5.17 to 14.03) | 10 (5.32 to 16.95) | 10 (5.20 to 17.49) | 7 (2.85 to 12.41) | 4 (1.33 to 9.23) |
| W human Serogroup (At Month 2) ≥ LLQ (39.6) | 48 (40.24 to 56.12) | 65 (57.55 to 71.95) | 96 (90.47 to 98.62) | 67 (56.95 to 75.45) | 77 (68.81 to 84.31) | 60 (50.95 to 68.88) |
| W human Serogroup (At Month 2) ≥ 5 | 66 (58.21 to 73.29) | 90 (84.66 to 93.96) | 99 (95.41 to 99.98) | 92 (84.77 to 96.12) | 93 (86.56 to 96.60) | 93 (86.56 to 96.60) |
| W human Serogroup (At Month 2) ≥ 8 | 64 (56.30 to 71.57) | 86 (80.18 to 90.81) | 99 (95.41 to 99.98) | 92 (84.77 to 96.12) | 93 (86.56 to 96.60) | 89 (81.64 to 93.64) |
| W human Serogroup (At Month 2) ≥ 16 | 60 (52.52 to 68.07) | 82 (75.84 to 87.51) | 99 (95.41 to 99.98) | 81 (72.86 to 88.31) | 89 (82.60 to 94.25) | 80 (72.37 to 87.08) |
| W human Serogroup (At Month 2) ≥ 32 | 52 (44.49 to 60.36) | 69 (62.16 to 76.08) | 98 (94.06 to 99.80) | 72 (62.78 to 80.41) | 78 (69.69 to 85.01) | 65 (55.92 to 73.42) |
| W human Serogroup (At Month 2) ≥ 64 | 44 (36.05 to 51.83) | 50 (42.47 to 57.53) | 84 (76.19 to 90.10) | 52 (42.03 to 61.57) | 67 (58.45 to 75.65) | 44 (34.97 to 53.13) |
| W human Serogroup (At Month 2) ≥ 128 | 29 (22.16 to 36.65) | 31 (23.92 to 37.84) | 62 (52.84 to 70.91) | 33 (24.55 to 43.05) | 49 (39.67 to 57.95) | 27 (19.24 to 35.57) |
| W human Serogroup (At Month 3) ≥ LLQ (39.6) | 89 (83.01 to 93.28) | 97 (92.89 to 98.77) | 85 (77.15 to 90.78) | 68 (57.91 to 76.28) | 77 (68.81 to 84.31) | 97 (91.88 to 99.11) |
| W human Serogroup (At Month 3) ≥ 5 | 96 (92.11 to 98.63) | 99 (96.04 to 99.87) | 98 (94.06 to 99.80) | 94 (87.10 to 97.35) | 92 (85.56 to 96.03) | 100 (97.05 to 100) |
| W human Serogroup (At Month 3) ≥ 8 | 96 (92.11 to 98.63) | 99 (96.04 to 99.87) | 97 (92.81 to 99.48) | 90 (82.51 to 94.80) | 90 (83.58 to 94.86) | 100 (97.05 to 100) |
| W human Serogroup (At Month 3) ≥ 16 | 96 (91.30 to 98.25) | 99 (96.04 to 99.87) | 96 (90.47 to 98.62) | 81 (71.83 to 87.54) | 86 (78.80 to 91.74) | 99 (95.55 to 99.98) |
| W human Serogroup (At Month 3) ≥ 32 | 91 (85.19 to 94.72) | 98 (94.41 to 99.39) | 91 (84.06 to 95.29) | 73 (63.76 to 81.22) | 78 (69.69 to 85.01) | 98 (93.04 to 99.49) |
| W human Serogroup (At Month 3) ≥ 64 | 80 (73.27 to 86.08) | 93 (88.64 to 96.51) | 77 (68.73 to 84.48) | 50 (40.22 to 59.78) | 64 (55.09 to 72.67) | 91 (84.56 to 95.45) |
| W human Serogroup (At Month 3) ≥ 128 | 61 (53.15 to 68.66) | 74 (66.83 to 80.14) | 50 (41.11 to 59.71) | 33 (24.55 to 43.05) | 44 (34.97 to 53.13) | 70 (61.00 to 77.86) |
| W human Serogroup (At Month 7) ≥ LLQ (39.6) | 60 (51.90 to 67.49) | 82 (75.23 to 87.03) | 79 (70.57 to 85.92) | 99 (94.95 to 99.98) | 74 (65.30 to 81.48) | 99 (95.55 to 99.98) |
| W human Serogroup (At Month 7) ≥ 5 | 71 (63.35 to 77.84) | 97 (92.89 to 98.77) | 96 (90.47 to 98.62) | 100 (96.64 to 100) | 93 (86.56 to 96.60) | 100 (97.05 to 100) |
| W human Serogroup (At Month 7) ≥ 8 | 70 (62.70 to 77.28) | 95 (90.72 to 97.69) | 95 (89.35 to 98.13) | 100 (96.64 to 100) | 91 (84.56 to 95.45) | 100 (97.05 to 100) |
| W human Serogroup (At Month 7) ≥ 16 | 69 (61.41 to 76.15) | 92 (87.29 to 95.68) | 91 (84.06 to 95.29) | 100 (96.64 to 100) | 87 (79.74 to 92.38) | 100 (97.05 to 100) |
| W human Serogroup (At Month 7) ≥ 32 | 63 (55.03 to 70.41) | 84 (78.31 to 89.41) | 84 (76.19 to 90.10) | 100 (96.64 to 100) | 76 (67.93 to 83.61) | 99 (95.55 to 99.98) |
| W human Serogroup (At Month 7) ≥ 64 | 49 (40.85 to 56.73) | 68 (60.42 to 74.54) | 67 (58.02 to 75.55) | 97 (92.10 to 99.42) | 59 (49.31 to 67.35) | 98 (93.04 to 99.49) |
| W human Serogroup (At Month 7) ≥ 128 | 31 (23.85 to 38.59) | 41 (33.31 to 48.11) | 34 (25.98 to 43.72) | 87 (79.21 to 92.73) | 34 (25.84 to 43.24) | 82 (74.18 to 88.44) |
| W human Serogroup (At Month 13) ≥ LLQ (39.6) | 47 (39.04 to 54.90) | 64 (56.41 to 70.90) | 66 (56.28 to 74.02) | 82 (73.90 to 89.06) | 98 (93.04 to 99.49) | 84 (76.01 to 89.78) |
| W human Serogroup (At Month 13) ≥ 5 | 62 (54.40 to 69.83) | 93 (87.97 to 96.10) | 90 (83.05 to 94.68) | 99 (94.95 to 99.98) | 99 (95.55 to 99.98) | 98 (94.25 to 99.80) |
| W human Serogroup (At Month 13) ≥ 8 | 60 (52.52 to 68.07) | 90 (84.66 to 93.96) | 90 (83.05 to 94.68) | 98 (93.47 to 99.77) | 99 (95.55 to 99.98) | 98 (94.25 to 99.80) |
| W human Serogroup (At Month 13) ≥ 16 | 57 (48.79 to 64.54) | 84 (77.69 to 88.94) | 81 (72.42 to 87.34) | 94 (87.10 to 97.35) | 99 (95.55 to 99.98) | 96 (90.77 to 98.67) |
| W human Serogroup (At Month 13) ≥ 32 | 50 (42.05 to 57.95) | 71 (63.90 to 77.61) | 72 (63.32 to 80.08) | 85 (77.06 to 91.29) | 98 (94.25 to 99.80) | 89 (82.60 to 94.25) |
| W human Serogroup (At Month 13) ≥ 64 | 35 (27.28 to 42.43) | 44 (36.52 to 51.47) | 48 (38.66 to 57.25) | 73 (63.76 to 81.22) | 98 (93.04 to 99.49) | 68 (59.29 to 76.39) |
| W human Serogroup (At Month 13) ≥ 128 | 21 (14.99 to 28.07) | 22 (16.38 to 29.01) | 28 (19.92 to 36.68) | 43 (33.13 to 52.47) | 94 (88.63 to 97.68) | 45 (35.75 to 53.94) |
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against Y human serogroup was assessed.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Y human Serogroup (At Month 0) ≥ LLQ (14.7) | 15 (10.13 to 20.80) | 10 (6.04 to 15.34) | 13 (7.82 to 20.75) | 6 (2.60 to 12.67) | 13 (7.38 to 19.65) | 7 (3.05 to 12.10) |
| Y human Serogroup (At Month 0) ≥ 5 | 16 (11.03 to 21.99) | 11 (6.92 to 16.64) | 15 (9.14 to 22.67) | 7 (3.19 to 13.83) | 17 (10.54 to 24.16) | 9 (4.61 to 14.80) |
| Y human Serogroup (At Month 0) ≥ 8 | 16 (11.03 to 21.99) | 11 (6.92 to 16.64) | 14 (8.47 to 21.71) | 7 (3.19 to 13.83) | 16 (9.89 to 23.27) | 9 (4.61 to 14.80) |
| Y human Serogroup (At Month 0) ≥ 16 | 15 (10.13 to 20.80) | 10 (6.04 to 15.34) | 13 (7.17 to 19.78) | 6 (2.60 to 12.67) | 12 (6.76 to 18.73) | 6 (2.55 to 11.18) |
| Y human Serogroup (At Month 0) ≥ 32 | 9 (5.36 to 14.08) | 3 (0.91 to 6.36) | 8 (4.07 to 14.79) | 3 (0.57 to 7.76) | 8 (3.84 to 14.00) | 4 (1.62 to 9.29) |
| Y human Serogroup (At Month 0) ≥ 64 | 2 (0.58 to 5.36) | 2 (0.35 to 4.79) | 4 (1.37 to 9.46) | 0 (0 to 3.30) | 5 (1.75 to 10.00) | 3 (0.80 to 7.31) |
| Y human Serogroup (At Month 0) ≥ 128 | 0 (0 to 1.94) | 1 (0.01 to 3.06) | 1 (0.02 to 4.56) | 0 (0 to 3.30) | 1 (0.02 to 4.31) | 1 (0.02 to 4.00) |
| Y human Serogroup (At Month 2) ≥ LLQ (14.7) | 21 (15.19 to 27.25) | 66 (58.70 to 72.99) | 85 (77.33 to 90.86) | 60 (50.22 to 69.22) | 72 (62.98 to 79.29) | 61 (52.62 to 69.51) |
| Y human Serogroup (At Month 2) ≥ 5 | 27 (20.91 to 34.08) | 72 (64.48 to 78.12) | 90 (83.18 to 94.73) | 65 (55.79 to 74.26) | 78 (69.74 to 84.82) | 65 (56.35 to 72.91) |
| Y human Serogroup (At Month 2) ≥ 8 | 26 (19.95 to 32.95) | 70 (62.74 to 76.59) | 89 (82.19 to 94.10) | 62 (52.07 to 70.92) | 76 (68.03 to 83.46) | 64 (54.85 to 71.56) |
| Y human Serogroup (At Month 2) ≥ 16 | 20 (14.72 to 26.67) | 64 (56.41 to 70.90) | 85 (77.33 to 90.86) | 58 (48.39 to 67.52) | 69 (60.49 to 77.17) | 60 (51.14 to 68.13) |
| Y human Serogroup (At Month 2) ≥ 32 | 13 (8.35 to 18.40) | 47 (39.75 to 54.79) | 75 (66.27 to 82.45) | 47 (37.68 to 57.02) | 54 (44.48 to 62.44) | 50 (41.70 to 59.01) |
| Y human Serogroup (At Month 2) ≥ 64 | 5 (2.21 to 8.89) | 31 (23.92 to 37.84) | 59 (49.82 to 68.05) | 30 (21.63 to 39.48) | 39 (30.08 to 47.63) | 39 (31.18 to 48.12) |
| Y human Serogroup (At Month 2) ≥ 128 | 1 (0.13 to 3.79) | 14 (9.19 to 19.82) | 39 (30.39 to 48.50) | 12 (6.45 to 19.36) | 23 (15.86 to 31.12) | 23 (16.56 to 31.34) |
| Y human Serogroup (At Month 3) ≥ LLQ (14.7) | 27 (20.43 to 33.52) | 92 (87.29 to 95.68) | 80 (71.72 to 86.75) | 58 (48.39 to 67.52) | 62 (53.17 to 70.65) | 90 (83.45 to 94.30) |
| Y human Serogroup (At Month 3) ≥ 5 | 33 (26.31 to 40.19) | 94 (89.33 to 96.91) | 84 (76.38 to 90.19) | 65 (54.85 to 73.43) | 70 (61.32 to 77.88) | 93 (86.99 to 96.44) |
| Y human Serogroup (At Month 3) ≥ 8 | 30 (23.84 to 37.43) | 93 (88.64 to 96.51) | 83 (75.44 to 89.51) | 60 (50.22 to 69.22) | 67 (58.03 to 75.02) | 93 (86.99 to 96.44) |
| Y human Serogroup (At Month 3) ≥ 16 | 26 (19.95 to 32.95) | 92 (86.63 to 95.26) | 79 (70.80 to 86.04) | 57 (47.48 to 66.66) | 59 (49.98 to 67.70) | 90 (83.45 to 94.30) |
| Y human Serogroup (At Month 3) ≥ 32 | 18 (12.86 to 24.34) | 84 (77.69 to 88.94) | 68 (58.35 to 75.77) | 44 (34.20 to 53.42) | 44 (35.30 to 53.17) | 83 (75.88 to 89.05) |
| Y human Serogroup (At Month 3) ≥ 64 | 9 (4.94 to 13.45) | 68 (61.00 to 75.05) | 47 (37.51 to 55.99) | 24 (16.06 to 32.68) | 31 (23.55 to 40.33) | 65 (56.35 to 72.91) |
| Y human Serogroup (At Month 3) ≥ 128 | 2 (0.58 to 5.36) | 39 (32.25 to 46.99) | 28 (19.75 to 36.40) | 16 (10.00 to 24.62) | 23 (15.86 to 31.12) | 47 (38.15 to 55.43) |
| Y human Serogroup (At Month 7) ≥ LLQ (14.7) | 23 (17.07 to 29.55) | 78 (70.99 to 83.62) | 72 (62.72 to 79.51) | 95 (88.51 to 97.97) | 54 (44.48 to 62.44) | 97 (92.69 to 99.20) |
| Y human Serogroup (At Month 7) ≥ 5 | 26 (19.95 to 32.95) | 86 (79.56 to 90.34) | 80 (71.72 to 86.75) | 95 (89.71 to 98.51) | 69 (59.67 to 76.45) | 99 (94.83 to 99.82) |
| Y human Serogroup (At Month 7) ≥ 8 | 26 (19.46 to 32.39) | 84 (77.69 to 88.94) | 77 (68.07 to 83.90) | 95 (89.71 to 98.51) | 64 (54.78 to 72.12) | 98 (93.73 to 99.55) |
| Y human Serogroup (At Month 7) ≥ 16 | 22 (16.13 to 28.40) | 74 (66.83 to 80.14) | 69 (60.09 to 77.27) | 94 (87.33 to 97.40) | 52 (42.93 to 60.91) | 97 (92.69 to 99.20) |
| Y human Serogroup (At Month 7) ≥ 32 | 13 (8.35 to 18.40) | 63 (55.27 to 69.85) | 54 (44.83 to 63.29) | 87 (79.57 to 92.86) | 40 (31.56 to 49.22) | 91 (85.20 to 95.39) |
| Y human Serogroup (At Month 7) ≥ 64 | 3 (0.87 to 6.10) | 37 (30.15 to 44.73) | 35 (26.52 to 44.24) | 79 (70.30 to 86.26) | 27 (19.31 to 35.35) | 75 (67.08 to 82.16) |
| Y human Serogroup (At Month 7) ≥ 128 | 1 (0.01 to 2.93) | 14 (9.66 to 20.44) | 22 (14.67 to 30.11) | 57 (47.48 to 66.66) | 13 (8.00 to 20.56) | 57 (48.20 to 65.36) |
| Y human Serogroup (At Month 13) ≥ LLQ (14.7) | 19 (13.32 to 24.93) | 64 (56.41 to 70.90) | 58 (48.15 to 66.47) | 78 (69.30 to 85.49) | 97 (92.13 to 99.14) | 82 (75.06 to 88.44) |
| Y human Serogroup (At Month 13) ≥ 5 | 25 (18.98 to 31.82) | 76 (68.61 to 81.64) | 73 (64.49 to 80.99) | 91 (83.92 to 95.55) | 97 (92.13 to 99.14) | 91 (85.20 to 95.39) |
| Y human Serogroup (At Month 13) ≥ 8 | 24 (18.03 to 30.69) | 71 (63.90 to 77.61) | 63 (54.05 to 71.94) | 84 (75.38 to 90.00) | 97 (92.13 to 99.14) | 87 (80.03 to 92.02) |
| Y human Serogroup (At Month 13) ≥ 16 | 18 (12.40 to 23.76) | 61 (53.58 to 68.27) | 55 (45.65 to 64.09) | 76 (67.32 to 83.94) | 97 (92.13 to 99.14) | 81 (73.44 to 87.21) |
| Y human Serogroup (At Month 13) ≥ 32 | 10 (5.77 to 14.71) | 43 (35.45 to 50.35) | 40 (31.17 to 49.34) | 60 (50.22 to 69.22) | 93 (86.97 to 96.71) | 69 (60.13 to 76.27) |
| Y human Serogroup (At Month 13) ≥ 64 | 3 (1.18 to 6.82) | 21 (15.39 to 27.81) | 23 (15.38 to 31.02) | 41 (31.63 to 50.69) | 92 (86.00 to 96.16) | 46 (37.44 to 54.70) |
| Y human Serogroup (At Month 13) ≥ 128 | 1 (0.13 to 3.79) | 9 (5.17 to 14.03) | 11 (5.90 to 17.81) | 21 (13.74 to 29.70) | 73 (64.65 to 80.69) | 28 (21.09 to 36.80) |
The kinetic of immune response (at Months 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with two-, three- and four-fold titer rise against serogroups A, C, W and Y and serogroup B test strains was assessed. The two/three/four fold titer rise is defined as: a) for subjects with prevaccination hSBA titers ≤ LLQ, a postvaccination hSBA ≥ 2/3/4 LLQ; b) for subjects with a prevaccination hSBA titers ≥ LLQ, an increase of at least 2/3/4 times of the prevaccination hSBA titer.
| Percentages of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| NZ98/254 Strain ≥ 2-fold (At Month 2) | 18 (12.86 to 24.34) | 13 (8.49 to 18.69) | 28 (19.75 to 36.40) | 9 (4.36 to 15.81) | 21 (14.62 to 29.62) | 12 (6.98 to 18.67) |
| NZ98/254 Strain ≥ 3-fold (At Month 2) | 14 (9.24 to 19.60) | 9 (5.44 to 14.30) | 19 (12.56 to 27.36) | 9 (4.36 to 15.81) | 17 (11.28 to 25.23) | 7 (3.64 to 13.30) |
| NZ98/254 Strain ≥ 4-fold (At Month 2) | 11 (7.05 to 16.57) | 8 (4.61 to 13.02) | 17 (10.49 to 24.56) | 7 (3.13 to 13.59) | 17 (10.62 to 24.34) | 7 (3.12 to 12.37) |
| NZ98/254 Strain ≥ 2-fold (At Month 3) | 73 (66.48 to 79.57) | 42 (34.43 to 49.08) | 18 (11.17 to 25.50) | 9 (4.36 to 15.81) | 13 (8.06 to 20.72) | 43 (34.76 to 52.11) |
| NZ98/254 Strain ≥ 3-fold (At Month 3) | 61 (53.81 to 68.18) | 32 (25.25 to 39.13) | 13 (7.17 to 19.78) | 5 (1.99 to 11.30) | 10 (5.61 to 17.00) | 28 (20.91 to 36.79) |
| NZ98/254 Strain ≥ 4-fold (At Month 3) | 47 (39.51 to 54.21) | 22 (15.92 to 28.26) | 9 (4.67 to 15.81) | 4 (0.98 to 8.89) | 9 (4.44 to 15.08) | 19 (12.45 to 26.30) |
| NZ98/254 Strain ≥ 2-fold (At Month 7) | 19 (13.32 to 24.93) | 12 (8.05 to 18.07) | 11 (5.90 to 17.81) | 45 (35.24 to 54.33) | 7 (3.32 to 13.13) | 54 (44.92 to 62.38) |
| NZ98/254 Strain ≥ 3-fold (At Month 7) | 11 (7.05 to 16.57) | 10 (6.30 to 15.57) | 7 (2.92 to 12.71) | 33 (24.44 to 42.56) | 6 (2.78 to 12.13) | 43 (34.76 to 52.11) |
| NZ98/254 Strain ≥ 4-fold (At Month 7) | 9 (5.36 to 14.08) | 8 (4.61 to 13.02) | 6 (2.38 to 11.65) | 24 (16.53 to 33.10) | 4 (1.30 to 9.02) | 33 (24.97 to 41.47) |
| NZ98/254 Strain ≥ 2-fold (At Month 13) | 11 (6.62 to 15.95) | 9 (5.44 to 14.30) | 7 (2.92 to 12.71) | 10 (5.01 to 16.89) | 49 (40.19 to 58.26) | 14 (8.76 to 21.25) |
| NZ98/254 Strain ≥ 3-fold (At Month 13) | 5 (2.58 to 9.56) | 7 (3.79 to 11.72) | 6 (2.38 to 11.65) | 9 (4.36 to 15.81) | 37 (28.12 to 45.55) | 7 (3.64 to 13.30) |
| NZ98/254 Strain ≥ 4-fold (At Month 13) | 4 (1.85 to 8.21) | 5 (2.62 to 9.72) | 5 (1.86 to 10.57) | 6 (2.55 to 12.45) | 26 (18.76 to 34.77) | 4 (1.66 to 9.49) |
| M14459 Strain ≥ 2-fold (At Month 2) | 14 (9.44 to 20.02) | 13 (8.32 to 18.65) | 34 (25.25 to 43.48) | 8 (3.88 to 15.23) | 23 (15.69 to 31.19) | 11 (6.40 to 17.79) |
| M14459 Strain ≥ 3-fold (At Month 2) | 10 (5.90 to 15.02) | 10 (6.07 to 15.43) | 23 (15.76 to 32.14) | 6 (2.07 to 11.70) | 15 (9.56 to 23.07) | 6 (2.61 to 11.42) |
| M14459 Strain ≥ 4-fold (At Month 2) | 7 (3.82 to 11.78) | 6 (2.71 to 10.03) | 15 (9.10 to 23.19) | 4 (1.02 to 9.21) | 12 (6.99 to 19.32) | 4 (1.22 to 8.49) |
| M14459 Strain ≥ 2-fold (At Month 3) | 65 (57.86 to 72.07) | 50 (42.72 to 57.82) | 24 (16.53 to 33.10) | 6 (2.65 to 12.90) | 14 (8.26 to 21.20) | 50 (41.25 to 58.75) |
| M14459 Strain ≥ 3-fold (At Month 3) | 49 (41.49 to 56.37) | 39 (31.38 to 46.10) | 10 (5.01 to 16.89) | 3 (0.58 to 7.90) | 11 (5.75 to 17.40) | 39 (30.52 to 47.60) |
| M14459 Strain ≥ 4-fold (At Month 3) | 38 (30.49 to 44.92) | 28 (22.01 to 35.70) | 4 (1.47 to 10.11) | 3 (0.58 to 7.90) | 7 (3.40 to 13.44) | 28 (20.24 to 36.00) |
| M14459 Strain ≥ 2-fold (At Month 7) | 16 (11.28 to 22.45) | 14 (9.25 to 19.92) | 9 (4.36 to 15.81) | 69 (58.88 to 77.12) | 7 (2.85 to 12.41) | 72 (63.21 to 79.09) |
| M14459 Strain ≥ 3-fold (At Month 7) | 12 (7.65 to 17.54) | 7 (3.92 to 12.10) | 6 (2.55 to 12.45) | 55 (44.76 to 64.24) | 6 (2.32 to 11.37) | 54 (45.65 to 63.10) |
| M14459 Strain ≥ 4-fold (At Month 7) | 8 (4.22 to 12.44) | 6 (3.11 to 10.73) | 4 (0.98 to 8.89) | 48 (38.43 to 57.97) | 5 (1.81 to 10.32) | 49 (39.79 to 57.29) |
| M14459 Strain ≥ 2-fold (At Month 13) | 11 (7.21 to 16.92) | 9 (5.63 to 14.77) | 6 (2.55 to 12.45) | 10 (5.20 to 17.49) | 74 (65.30 to 81.48) | 12 (6.98 to 18.67) |
| M14459 Strain ≥ 3-fold (At Month 13) | 8 (4.22 to 12.44) | 4 (1.95 to 8.62) | 4 (1.47 to 10.11) | 7 (3.25 to 14.07) | 59 (50.12 to 68.11) | 6 (2.61 to 11.42) |
| M14459 Strain ≥ 4-fold (At Month 13) | 3 (1.21 to 6.96) | 4 (1.59 to 7.89) | 3 (0.56 to 7.63) | 6 (2.07 to 11.70) | 51 (42.05 to 60.33) | 4 (1.66 to 9.49) |
| M07-0241084 Strain ≥ 2-fold (At Month 2) | 16 (11.49 to 22.58) | 11 (6.63 to 16.34) | 20 (12.89 to 28.02) | 5 (1.97 to 11.20) | 19 (12.45 to 27.14) | 8 (3.81 to 13.90) |
| M07-0241084 Strain ≥ 3-fold (At Month 2) | 12 (7.92 to 17.79) | 7 (3.57 to 11.61) | 9 (4.79 to 16.20) | 2 (0.22 to 6.25) | 12 (6.47 to 18.65) | 4 (1.28 to 8.88) |
| M07-0241084 Strain ≥ 4-fold (At Month 2) | 8 (4.53 to 12.82) | 5 (1.98 to 8.76) | 7 (3.00 to 13.03) | 2 (0.22 to 6.25) | 9 (4.63 to 15.68) | 1 (0.02 to 4.28) |
| M07-0241084 Strain ≥ 2-fold (At Month 3) | 37 (29.81 to 44.02) | 22 (16.26 to 29.02) | 11 (6.05 to 18.25) | 2 (0.22 to 6.25) | 8 (4.03 to 14.67) | 21 (14.38 to 29.19) |
| M07-0241084 Strain ≥ 3-fold (At Month 3) | 28 (21.40 to 34.64) | 12 (7.54 to 17.66) | 7 (3.00 to 13.03) | 1 (0.02 to 4.83) | 5 (1.84 to 10.48) | 17 (11.10 to 24.86) |
| M07-0241084 Strain ≥ 4-fold (At Month 3) | 19 (13.32 to 24.93) | 9 (5.29 to 14.34) | 4 (1.40 to 9.69) | 0 (0 to 3.21) | 4 (1.36 to 9.38) | 13 (7.93 to 20.41) |
| M07-0241084 Strain ≥ 2-fold (At Month 7) | 19 (13.32 to 24.93) | 13 (8.00 to 18.31) | 8 (3.58 to 14.10) | 43 (34.07 to 53.01) | 4 (1.36 to 9.38) | 42 (33.51 to 51.23) |
| M07-0241084 Strain ≥ 3-fold (At Month 7) | 11 (7.05 to 16.57) | 7 (3.99 to 12.30) | 6 (2.44 to 11.94) | 31 (22.61 to 40.36) | 1 (0.02 to 4.52) | 32 (24.06 to 40.85) |
| M07-0241084 Strain ≥ 4-fold (At Month 7) | 7 (4.13 to 12.18) | 6 (2.76 to 10.20) | 3 (0.94 to 8.52) | 19 (12.62 to 27.98) | 1 (0.02 to 4.52) | 22 (15.05 to 30.04) |
| M07-0241084 Strain ≥ 2-fold (At Month 13) | 13 (8.35 to 18.40) | 11 (7.08 to 17.00) | 8 (3.58 to 14.10) | 13 (7.62 to 20.95) | 41 (32.45 to 50.63) | 15 (9.18 to 22.21) |
| M07-0241084 Strain ≥ 3-fold (At Month 13) | 9 (4.94 to 13.45) | 7 (3.99 to 12.30) | 5 (1.90 to 10.83) | 9 (4.33 to 15.67) | 34 (25.53 to 43.05) | 10 (5.52 to 16.74) |
| M07-0241084 Strain ≥ 4-fold (At Month 13) | 5 (2.58 to 9.56) | 6 (2.76 to 10.20) | 4 (1.40 to 9.69) | 6 (2.53 to 12.35) | 21 (13.84 to 28.97) | 6 (2.74 to 11.94) |
| 96217 Strain ≥ 2-fold (At Month 2) | 34 (27.61 to 41.71) | 29 (22.65 to 36.48) | 88 (81.20 to 93.47) | 32 (23.63 to 41.63) | 31 (23.35 to 40.04) | 26 (18.84 to 35.24) |
| 96217 Strain ≥ 3-fold (At Month 2) | 26 (19.68 to 32.72) | 20 (14.09 to 26.27) | 81 (72.64 to 87.44) | 19 (12.00 to 27.22) | 18 (11.74 to 25.73) | 19 (12.45 to 27.14) |
| 96217 Strain ≥ 4-fold (At Month 2) | 18 (12.54 to 24.00) | 13 (8.37 to 18.76) | 76 (67.17 to 83.18) | 12 (6.33 to 19.03) | 14 (8.55 to 21.31) | 16 (9.73 to 23.43) |
| 96217 Strain ≥ 2-fold (At Month 3) | 97 (93.84 to 99.12) | 92 (87.16 to 95.63) | 85 (77.33 to 90.86) | 28 (19.64 to 36.93) | 23 (16.41 to 31.74) | 91 (84.32 to 95.37) |
| 96217 Strain ≥ 3-fold (At Month 3) | 96 (92.40 to 98.47) | 89 (83.18 to 93.00) | 76 (67.17 to 83.18) | 14 (8.39 to 22.16) | 17 (11.10 to 24.86) | 88 (81.35 to 93.53) |
| 96217 Strain ≥ 4-fold (At Month 3) | 94 (89.66 to 97.01) | 83 (76.20 to 87.85) | 69 (60.09 to 77.27) | 11 (5.66 to 17.97) | 13 (7.93 to 20.41) | 83 (75.63 to 89.60) |
| 96217 Strain ≥ 2-fold (At Month 7) | 81 (74.81 to 86.53) | 74 (66.48 to 79.91) | 64 (54.90 to 72.71) | 96 (91.11 to 99.02) | 16 (10.45 to 23.98) | 97 (91.75 to 99.09) |
| 96217 Strain ≥ 3-fold (At Month 7) | 73 (65.57 to 78.85) | 63 (55.38 to 70.03) | 52 (42.37 to 60.88) | 96 (91.11 to 99.02) | 9 (4.94 to 15.80) | 96 (90.62 to 98.64) |
| 96217 Strain ≥ 4-fold (At Month 7) | 61 (53.89 to 68.33) | 50 (42.43 to 57.57) | 42 (32.74 to 51.02) | 95 (88.70 to 98.01) | 7 (3.27 to 12.93) | 94 (88.44 to 97.64) |
| 96217 Strain ≥ 2-fold (At Month 13) | 65 (57.73 to 71.88) | 54 (46.32 to 61.42) | 52 (42.37 to 60.88) | 72 (63.07 to 80.36) | 96 (91.12 to 98.72) | 77 (68.32 to 84.04) |
| 96217 Strain ≥ 3-fold (At Month 13) | 53 (45.78 to 60.56) | 39 (32.10 to 46.91) | 34 (25.76 to 43.38) | 54 (44.78 to 63.90) | 95 (89.06 to 97.77) | 62 (52.71 to 70.65) |
| 96217 Strain ≥ 4-fold (At Month 13) | 35 (28.62 to 42.82) | 22 (16.57 to 29.32) | 28 (19.75 to 36.40) | 45 (35.24 to 54.33) | 93 (87.07 to 96.73) | 51 (41.99 to 60.43) |
| A human Serogroup ≥ 2-fold (At Month 2) | 12 (7.72 to 18.06) | 23 (17.07 to 29.92) | 78 (68.49 to 85.07) | 21 (13.62 to 29.99) | 38 (28.83 to 46.80) | 17 (10.54 to 24.16) |
| A human Serogroup ≥ 3-fold (At Month 2) | 9 (5.41 to 14.67) | 16 (11.19 to 22.55) | 64 (53.69 to 72.64) | 14 (8.22 to 22.47) | 30 (21.98 to 39.04) | 13 (7.38 to 19.65) |
| A human Serogroup ≥ 4-fold (At Month 2) | 6 (2.82 to 10.43) | 11 (6.55 to 16.17) | 50 (39.72 to 59.37) | 11 (6.05 to 19.11) | 20 (13.25 to 28.28) | 7 (3.29 to 13.03) |
| A human Serogroup ≥ 2-fold (At Month 3) | 80 (72.85 to 85.40) | 71 (63.52 to 77.35) | 61 (50.84 to 70.05) | 20 (12.83 to 28.93) | 24 (16.82 to 32.83) | 74 (65.49 to 81.39) |
| A human Serogroup ≥ 3-fold (At Month 3) | 66 (58.09 to 72.76) | 52 (44.64 to 59.77) | 41 (31.70 to 51.05) | 12 (6.76 to 20.24) | 18 (11.86 to 26.43) | 56 (46.83 to 64.70) |
| A human Serogroup ≥ 4-fold (At Month 3) | 56 (48.64 to 63.93) | 42 (34.79 to 49.75) | 31 (22.27 to 40.50) | 7 (2.72 to 13.25) | 14 (8.47 to 21.71) | 40 (31.56 to 49.22) |
| A human Serogroup ≥ 2-fold (At Month 7) | 27 (20.82 to 34.63) | 28 (21.11 to 34.71) | 25 (17.33 to 34.55) | 87 (78.64 to 92.51) | 8 (3.49 to 13.76) | 88 (81.27 to 93.24) |
| A human Serogroup ≥ 3-fold (At Month 7) | 17 (11.59 to 23.31) | 16 (11.19 to 22.55) | 16 (9.54 to 24.21) | 76 (66.89 to 83.96) | 6 (2.38 to 11.65) | 77 (68.88 to 84.14) |
| A human Serogroup ≥ 4-fold (At Month 7) | 11 (6.78 to 16.71) | 10 (5.66 to 14.85) | 13 (7.34 to 20.98) | 70 (60.78 to 78.98) | 5 (1.86 to 10.57) | 70 (61.32 to 77.88) |
| A human Serogroup ≥ 2-fold (At Month 13) | 16 (10.61 to 22.01) | 12 (7.91 to 18.11) | 18 (11.04 to 26.33) | 31 (22.72 to 41.22) | 85 (77.33 to 90.86) | 28 (20.71 to 37.02) |
| A human Serogroup ≥ 3-fold (At Month 13) | 9 (5.41 to 14.67) | 8 (4.37 to 12.84) | 11 (5.93 to 18.77) | 25 (16.86 to 34.14) | 80 (71.72 to 86.75) | 15 (9.25 to 22.37) |
| A human Serogroup ≥ 4-fold (At Month 13) | 5 (2.42 to 9.70) | 4 (1.60 to 7.93) | 9 (4.57 to 16.52) | 15 (8.97 to 23.56) | 78 (68.98 to 84.62) | 7 (3.29 to 13.03) |
| C human Serogroup ≥ 2-fold (At Month 2) | 24 (18.23 to 31.00) | 64 (56.41 to 70.71) | 95 (89.60 to 98.17) | 55 (45.66 to 64.58) | 73 (64.43 to 80.76) | 62 (52.61 to 69.93) |
| C human Serogroup ≥ 3-fold (At Month 2) | 15 (10.24 to 21.02) | 50 (42.84 to 57.69) | 91 (84.44 to 95.41) | 48 (38.79 to 57.80) | 59 (49.31 to 67.35) | 54 (44.89 to 62.62) |
| C human Serogroup ≥ 4-fold (At Month 2) | 9 (5.00 to 13.59) | 42 (34.43 to 49.08) | 88 (80.53 to 92.95) | 44 (34.58 to 53.46) | 50 (40.46 to 58.75) | 42 (32.97 to 50.51) |
| C human Serogroup ≥ 2-fold (At Month 3) | 80 (73.05 to 85.12) | 94 (89.61 to 96.99) | 93 (86.46 to 96.57) | 58 (48.29 to 67.08) | 65 (55.92 to 73.42) | 98 (93.40 to 99.52) |
| C human Serogroup ≥ 3-fold (At Month 3) | 64 (56.63 to 70.87) | 90 (85.06 to 94.13) | 90 (83.45 to 94.81) | 47 (37.94 to 56.94) | 50 (40.46 to 58.75) | 96 (91.25 to 98.74) |
| C human Serogroup ≥ 4-fold (At Month 3) | 49 (41.54 to 56.34) | 87 (81.31 to 91.51) | 83 (74.90 to 89.02) | 41 (32.09 to 50.83) | 42 (33.42 to 51.51) | 92 (85.36 to 95.70) |
| C human Serogroup ≥ 2-fold (At Month 7) | 29 (22.62 to 36.12) | 86 (80.70 to 91.06) | 89 (81.50 to 93.58) | 97 (92.50 to 99.45) | 50 (40.46 to 58.75) | 98 (94.55 to 99.81) |
| C human Serogroup ≥ 3-fold (At Month 7) | 16 (10.70 to 21.62) | 80 (73.50 to 85.51) | 79 (70.35 to 85.58) | 94 (87.76 to 97.50) | 37 (28.09 to 45.75) | 98 (94.55 to 99.81) |
| C human Serogroup ≥ 4-fold (At Month 7) | 10 (6.26 to 15.49) | 71 (64.26 to 77.75) | 72 (63.29 to 79.87) | 92 (85.54 to 96.33) | 28 (19.96 to 36.43) | 98 (93.40 to 99.52) |
| C human Serogroup ≥ 2-fold (At Month 13) | 19 (13.94 to 25.77) | 73 (65.97 to 79.23) | 74 (65.04 to 81.32) | 82 (73.23 to 88.22) | 97 (91.88 to 99.11) | 92 (86.31 to 96.25) |
| C human Serogroup ≥ 3-fold (At Month 13) | 13 (8.89 to 19.20) | 64 (56.41 to 70.71) | 61 (52.24 to 70.14) | 70 (60.89 to 78.38) | 96 (90.77 to 98.67) | 89 (82.59 to 93.99) |
| C human Serogroup ≥ 4-fold (At Month 13) | 10 (5.84 to 14.86) | 51 (43.91 to 58.75) | 53 (44.03 to 62.36) | 56 (46.54 to 65.42) | 93 (87.59 to 97.15) | 85 (77.24 to 90.34) |
| W human Serogroup ≥ 2-fold (At Month 2) | 24 (17.71 to 31.41) | 32 (24.95 to 39.00) | 65 (55.42 to 73.24) | 35 (26.24 to 44.96) | 50 (41.25 to 59.54) | 33 (25.09 to 42.40) |
| W human Serogroup ≥ 3-fold (At Month 2) | 17 (11.28 to 23.31) | 19 (13.93 to 25.99) | 52 (42.75 to 61.34) | 25 (17.17 to 34.25) | 40 (31.12 to 49.05) | 22 (14.99 to 30.31) |
| W human Serogroup ≥ 4-fold (At Month 2) | 11 (6.72 to 16.99) | 16 (11.06 to 22.31) | 42 (33.03 to 51.41) | 18 (10.94 to 26.10) | 34 (25.84 to 43.24) | 18 (11.56 to 25.82) |
| W human Serogroup ≥ 2-fold (At Month 3) | 67 (59.48 to 74.44) | 78 (71.59 to 84.12) | 55 (46.07 to 64.57) | 34 (25.40 to 44.01) | 46 (37.31 to 55.56) | 76 (67.93 to 83.61) |
| W human Serogroup ≥ 3-fold (At Month 3) | 54 (46.32 to 62.16) | 65 (57.55 to 71.95) | 39 (29.87 to 48.02) | 23 (15.57 to 32.25) | 34 (25.84 to 43.24) | 67 (58.45 to 75.65) |
| W human Serogroup ≥ 4-fold (At Month 3) | 43 (34.87 to 50.59) | 57 (49.09 to 64.02) | 30 (22.17 to 39.35) | 19 (12.46 to 28.17) | 28 (20.69 to 37.29) | 56 (46.87 to 65.03) |
| W human Serogroup ≥ 2-fold (At Month 7) | 31 (24.42 to 39.23) | 51 (43.57 to 58.62) | 43 (33.83 to 52.25) | 90 (82.51 to 94.80) | 41 (31.89 to 49.88) | 89 (81.64 to 93.64) |
| W human Serogroup ≥ 3-fold (At Month 7) | 22 (15.53 to 28.74) | 30 (23.41 to 37.26) | 29 (20.67 to 37.57) | 81 (71.83 to 87.54) | 28 (19.96 to 36.43) | 80 (72.37 to 87.08) |
| W human Serogroup ≥ 4-fold (At Month 7) | 13 (8.21 to 19.13) | 21 (14.91 to 27.20) | 17 (10.58 to 24.76) | 73 (63.76 to 81.22) | 20 (13.61 to 28.52) | 73 (64.43 to 80.76) |
| W human Serogroup ≥ 2-fold (At Month 13) | 20 (13.92 to 26.73) | 26 (19.36 to 32.58) | 32 (23.69 to 41.10) | 56 (46.60 to 66.00) | 94 (88.63 to 97.68) | 61 (51.77 to 69.64) |
| W human Serogroup ≥ 3-fold (At Month 13) | 9 (4.81 to 14.07) | 13 (8.28 to 18.55) | 17 (10.58 to 24.76) | 38 (28.80 to 47.81) | 92 (85.56 to 96.03) | 46 (36.53 to 54.75) |
| W human Serogroup ≥ 4-fold (At Month 13) | 7 (3.44 to 11.82) | 11 (6.48 to 15.99) | 13 (7.88 to 20.91) | 27 (18.78 to 36.24) | 89 (82.60 to 94.25) | 29 (21.41 to 38.15) |
| Y human Serogroup ≥ 2-fold (At Month 2) | 6 (2.96 to 10.23) | 49 (41.38 to 56.43) | 74 (65.38 to 81.72) | 47 (37.68 to 57.02) | 53 (43.70 to 61.68) | 51 (42.42 to 59.73) |
| Y human Serogroup ≥ 3-fold (At Month 2) | 4 (1.51 to 7.52) | 39 (32.25 to 46.99) | 64 (54.90 to 72.71) | 40 (30.78 to 49.78) | 41 (32.30 to 50.02) | 43 (34.64 to 51.80) |
| Y human Serogroup ≥ 4-fold (At Month 2) | 2 (0.58 to 5.36) | 32 (25.46 to 39.58) | 58 (48.15 to 66.47) | 33 (24.08 to 42.33) | 36 (27.88 to 45.22) | 37 (29.13 to 45.89) |
| Y human Serogroup ≥ 2-fold (At Month 3) | 10 (5.77 to 14.71) | 84 (78.31 to 89.41) | 66 (56.62 to 74.24) | 45 (35.93 to 55.23) | 46 (36.81 to 54.74) | 83 (75.88 to 89.05) |
| Y human Serogroup ≥ 3-fold (At Month 3) | 7 (3.73 to 11.53) | 80 (73.40 to 85.58) | 55 (45.65 to 64.09) | 35 (25.74 to 44.21) | 35 (26.43 to 43.60) | 75 (67.08 to 82.16) |
| Y human Serogroup ≥ 4-fold (At Month 3) | 4 (1.85 to 8.21) | 68 (61.00 to 75.05) | 48 (39.12 to 57.63) | 29 (20.82 to 38.52) | 31 (23.55 to 40.33) | 66 (57.86 to 74.26) |
| Y human Serogroup ≥ 2-fold (At Month 7) | 5 (2.21 to 8.89) | 60 (52.45 to 67.22) | 51 (41.55 to 60.07) | 90 (82.81 to 94.90) | 39 (30.08 to 47.63) | 92 (86.09 to 95.92) |
| Y human Serogroup ≥ 3-fold (At Month 7) | 3 (1.18 to 6.82) | 48 (40.29 to 55.34) | 44 (35.11 to 53.52) | 83 (74.35 to 89.27) | 28 (20.71 to 37.02) | 87 (80.03 to 92.02) |
| Y human Serogroup ≥ 4-fold (At Month 7) | 3 (0.87 to 6.10) | 41 (33.31 to 48.11) | 38 (29.61 to 47.65) | 79 (70.30 to 86.26) | 23 (15.86 to 31.12) | 76 (67.87 to 82.80) |
| Y human Serogroup ≥ 2-fold (At Month 13) | 5 (2.21 to 8.89) | 43 (35.45 to 50.35) | 38 (29.61 to 47.65) | 60 (50.22 to 69.22) | 94 (88.97 to 97.76) | 72 (63.20 to 78.91) |
| Y human Serogroup ≥ 3-fold (At Month 13) | 3 (1.18 to 6.82) | 34 (27.01 to 41.30) | 28 (20.49 to 37.28) | 48 (38.55 to 57.91) | 91 (84.08 to 95.02) | 54 (45.30 to 62.56) |
| Y human Serogroup ≥ 4-fold (At Month 13) | 2 (0.58 to 5.36) | 25 (18.86 to 31.99) | 23 (16.10 to 31.93) | 45 (35.93 to 55.23) | 89 (82.20 to 93.84) | 47 (38.15 to 55.43) |
The area under the curve for percentage of subjects with hSBA titers ≥ LLQ for all serogroups (A, C, W and Y) and for all serogroup B test strains (M14459, 96217, NZ98/254 and M07-0241084) was summarized overall (from Month 0 to Month 13) and by period (from Month 0 to Month 2, Month 2 to Month 3, Month 3 to Month 7 and Month 7 to Month 13) by vaccine groups. It was computed as the sum of the trapezoidal areas and the time unit used was the month. AUC 0_13 = (r0+r2)(2-0)/2 + (r2+r3)(3-2)/2 + (r3+r7)(7-3)/2 + (r7+r13)(13-7)/2 with ri = percentages of subjects with both hSBA titers \>= LLQ against N. meningitis for all serogroups A, C, W and Y and for all serogroup B test strains at Month 1.
| Percentage of subjects | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Serogroup A- Month 0-2 (LLQ-22.7) | 26.52 | 38.01 | 98.62 | 38.05 | 57.12 | 27.86 |
| Serogroup A- Month 2-3 (LLQ-22.7) | 57.69 | 60.98 | 86.91 | 33.40 | 47.00 | 59.13 |
| Serogroup A- Month 3-7 (LLQ-22.7) | 292.53 | 264.81 | 243.86 | 252.54 | 119.41 | 370.46 |
| Serogroup A- Month 7-13 (LLQ-22.7) | 256.04 | 214.62 | 217.88 | 446.58 | 343.24 | 436.76 |
| B M14459- Month 0-2 (LLQ-8.0) | 35.10 | 27.81 | 67.02 | 21.09 | 40.10 | 18.57 |
| B M14459- Month 2-3 (LLQ-8.0) | 55.45 | 46.06 | 52.36 | 16.53 | 30.88 | 44.90 |
| B M14459- Month 3-7 (LLQ-8.0) | 228.61 | 196.15 | 117.62 | 206.84 | 84.60 | 325.33 |
| B M14459- Month 7-13 (LLQ-8.0) | 162.94 | 141.79 | 82.51 | 329.36 | 309.09 | 347.86 |
| B 96217- Month 0-2 (LLQ-8.6) | 93.52 | 91.00 | 124.70 | 88.27 | 83.08 | 79.10 |
| B 96217- Month 2-3 (LLQ-8.6) | 85.03 | 80.02 | 95.77 | 58.55 | 52.33 | 74.25 |
| B 96217- Month 3-7 (LLQ-8.6) | 388.93 | 373.02 | 361.75 | 307.65 | 172.73 | 392.59 |
| B 96217- Month 7-13 (LLQ-8.6) | 545.92 | 515.49 | 495.00 | 561.47 | 411.36 | 578.42 |
| B NZ98/254- Month 0-2 (LLQ-8.2) | 30.27 | 25.84 | 48.92 | 22.37 | 31.33 | 20.13 |
| B NZ98/254- Month 2-3 (LLQ-8.2) | 55.56 | 40.77 | 37.21 | 15.89 | 24.05 | 42.93 |
| B NZ98/254- Month 3-7 (LLQ-8.2) | 227.81 | 162.89 | 92.78 | 156.65 | 65.46 | 282.91 |
| B NZ98/254- Month 7-13 (LLQ-8.2) | 142.59 | 105.40 | 90.34 | 242.66 | 257.90 | 277.24 |
| B M07-0241084- Month 0-2 (LLQ-8.9) | 57.74 | 43.20 | 53.67 | 42.74 | 58.93 | 47.53 |
| B M07-0241084- Month 2-3 (LLQ-8.9) | 52.46 | 37.16 | 34.01 | 28.33 | 34.47 | 41.65 |
| B M07-0241084- Month 3-7 (LLQ-8.9) | 213.53 | 151.20 | 111.63 | 190.79 | 110.94 | 251.09 |
| B M07-0241084- Month 7-13 (LLQ-8.9) | 217.26 | 159.73 | 145.97 | 301.71 | 282.69 | 320.48 |
| Serogroup C- Month 0-2(LLQ-5.2) | 102.82 | 129.30 | 148.03 | 126.63 | 135.79 | 128.34 |
| Serogroup C- Month 2-3(LLQ-5.2) | 78.78 | 91.97 | 99.22 | 82.97 | 88.21 | 92.85 |
| Serogroup C- Month 3-7(LLQ-5.2) | 331.60 | 390.80 | 390.79 | 360.70 | 339.12 | 398.53 |
| Serogroup C- Month 7-13(LLQ-5.2) | 382.55 | 567.41 | 574.69 | 589.70 | 545.04 | 595.68 |
| Serogroup W-Month 0-2(LLQ-39.6) | 75.66 | 93.12 | 124.89 | 85.71 | 103.94 | 84.23 |
| Serogroup W-Month 2-3(LLQ-39.6) | 68.51 | 81.75 | 90.33 | 65.66 | 75.19 | 78.97 |
| Serogroup W-Month 3-7(LLQ-39.6) | 293.42 | 359.84 | 327.79 | 331.64 | 297.71 | 392.61 |
| Serogroup W-Month 7-13(LLQ-39.6) | 305.31 | 444.54 | 434.34 | 543.61 | 512.92 | 550.19 |
| Serogroup Y-Month 0-2(LLQ-14.7) | 36.25 | 76.31 | 99.44 | 67.83 | 84.92 | 67.58 |
| Serogroup Y-Month 2-3(LLQ-14.7) | 24.51 | 79.32 | 83.26 | 58.88 | 67.70 | 75.50 |
| Serogroup Y-Month 3-7(LLQ-14.7) | 100.05 | 339.26 | 339.26 | 303.62 | 234.85 | 373.95 |
| Serogroup Y-Month 7-13(LLQ-14.7) | 125.13 | 425.13 | 389.69 | 520.64 | 454.48 | 537.41 |
Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity within 30 minutes after each vaccination. Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).
| Participants | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Any Induration(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Induration(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Induration(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Induration(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Induration(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Induration(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Induration(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Induration(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Induration(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Induration(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Erythema(1st vaccination) | 1 | 0 | 0 | 0 | 1 | 0 |
| Grade 3 Erythema(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Erythema(2nd vaccination) | 2 | 0 | 0 | 1 | 0 | 0 |
| Grade 3 Erythema(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Erythema(3rd vaccination) | 0 | 1 | 0 | 1 | 0 | 0 |
| Grade 3 Erythema(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Erythema(4th vaccination) | 0 | 1 | 0 | 0 | 0 | 1 |
| Grade 3 Erythema(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Erythema(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Erythema(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Pain(1st vaccination) | 19 | 4 | 12 | 8 | 17 | 13 |
| Grade 3 Pain(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Pain(2nd vaccination) | 10 | 12 | 11 | 9 | 14 | 9 |
| Grade 3 Pain(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Pain(3rd vaccination) | 10 | 11 | 8 | 7 | 5 | 13 |
| Grade 3 Pain(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Pain(4th vaccination) | 28 | 22 | 7 | 14 | 8 | 17 |
| Grade 3 Pain(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Pain(5th vaccination) | 19 | 16 | 12 | 15 | 13 | 12 |
| Grade 3 Pain(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea(1st vaccination) | 0 | 0 | 2 | 1 | 2 | 2 |
| Grade 3 Nausea(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea(2nd vaccination) | 2 | 0 | 1 | 1 | 0 | 0 |
| Grade 3 Nausea(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea(3rd vaccination) | 2 | 0 | 2 | 0 | 0 | 1 |
| Grade 3 Nausea(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea(4th vaccination) | 2 | 0 | 2 | 0 | 1 | 0 |
| Grade 3 Nausea(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea(5th vaccination) | 1 | 0 | 3 | 1 | 0 | 1 |
| Grade 3 Nausea(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Fatigue (1st vaccination) | 4 | 6 | 6 | 1 | 2 | 1 |
| Grade 3 Fatigue(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Fatigue (2nd vaccination) | 4 | 3 | 1 | 1 | 2 | 0 |
| Grade 3 Fatigue(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Fatigue (3rd vaccination) | 2 | 4 | 0 | 1 | 1 | 2 |
| Grade 3 Fatigue(3rd vaccination) | 0 | 0 | 0 | 1 | 0 | 0 |
| Any Fatigue (4th vaccination) | 2 | 1 | 1 | 0 | 1 | 3 |
| Grade 3 Fatigue(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Fatigue (5th vaccination) | 1 | 2 | 1 | 3 | 1 | 1 |
| Grade 3 Fatigue(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Myalgia(1st vaccination) | 0 | 1 | 0 | 0 | 0 | 0 |
| Grade 3 Myalgia(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Myalgia(2nd vaccination) | 0 | 0 | 1 | 0 | 3 | 1 |
| Grade 3 Myalgia(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Myalgia(3rd vaccination) | 0 | 0 | 0 | 1 | 0 | 0 |
| Grade 3 Myalgia(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Myalgia(4th vaccination) | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 3 Myalgia(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Myalgia(5th vaccination) | 0 | 4 | 1 | 0 | 1 | 0 |
| Grade 3 Myalgia(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Arthralgia(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Arthralgia(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Arthralgia(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Arthralgia(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Arthralgia(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Arthralgia(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Arthralgia(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Arthralgia(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Arthralgia(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Arthralgia(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Headache(1st vaccination) | 2 | 3 | 1 | 1 | 1 | 0 |
| Grade 3 Headache(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Headache(2nd vaccination) | 3 | 1 | 2 | 1 | 1 | 1 |
| Grade 3 Headache(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Headache(3rd vaccination) | 2 | 1 | 2 | 0 | 1 | 1 |
| Grade 3 Headache(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Headache(4th vaccination) | 3 | 2 | 0 | 0 | 1 | 1 |
| Grade 3 Headache(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Headache(5th vaccination) | 2 | 1 | 0 | 0 | 0 | 1 |
| Grade 3 Headache(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Chills(1st vaccination) | 0 | 1 | 1 | 0 | 2 | 2 |
| Grade 3 Chills(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Chills(2nd vaccination) | 1 | 1 | 1 | 1 | 0 | 0 |
| Gradec3 Chills(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Chills(3rd vaccination) | 1 | 1 | 0 | 0 | 0 | 0 |
| Grade 3 Chills(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Chills(4th vaccination) | 1 | 1 | 0 | 0 | 0 | 0 |
| Grade 3 Chills(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Chills(5th vaccination) | 1 | 1 | 0 | 0 | 0 | 0 |
| Grade 3 Chills(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Appetite Loss(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Appetite Loss(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Appetite Loss(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Appetite Loss(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Appetite Loss(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Appetite Loss(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Appetite Loss(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Appetite Loss(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| AnyAppetiteLoss(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 Appetite Loss(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Fever(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Fever(2nd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Fever(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Fever(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Fever(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pain/Fever prevention(1st vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pain/Fever prevention(2nd vaccination) | 0 | 2 | 0 | 0 | 0 | 0 |
| Pain/Fever prevention(3rd vaccination) | 1 | 0 | 0 | 0 | 0 | 0 |
| Pain/Fever prevention(4th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pain/Fever prevention(5th vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pain/Fever treatment(1st vaccination) | 0 | 0 | 1 | 0 | 0 | 0 |
| Pain/Fever treatment(2nd vaccination) | 1 | 0 | 0 | 0 | 0 | 1 |
| Pain/Fever treatment(3rd vaccination) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pain/Fever treatment(4th vaccination) | 0 | 1 | 0 | 0 | 0 | 0 |
| Pain/Fever treatment(5th vaccination) | 0 | 0 | 0 | 0 | 1 | 0 |
An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a participant and/or parent/legal guardian who has signed the informed consent. Number of participants reporting any unsolicited AE within 30 minutes after each vaccination.
| Participants | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Dizziness | 3 | 0 | 1 | 2 | 0 | 1 |
| Presyncope | 2 | 1 | 0 | 0 | 0 | 0 |
| Syncope | 0 | 1 | 1 | 0 | 1 | 0 |
| Injection site pain | 1 | 0 | 0 | 0 | 0 | 1 |
| Asthenia | 0 | 0 | 0 | 0 | 0 | 1 |
| Dyspnoea | 1 | 0 | 0 | 0 | 0 | 0 |
| Fatigue | 0 | 0 | 0 | 0 | 1 | 0 |
| Headache | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypoaesthesia | 0 | 0 | 0 | 0 | 1 | 0 |
| Injection site bruising | 1 | 0 | 0 | 0 | 0 | 0 |
| Injection site warmth | 0 | 1 | 0 | 0 | 0 | 0 |
| Pain | 0 | 0 | 0 | 0 | 1 | 0 |
| Paraesthesia | 1 | 0 | 0 | 0 | 0 | 0 |
| Pruritus allergic | 0 | 0 | 1 | 0 | 0 | 0 |
The number of participants reporting unsolicited AEs and possibly or probably related unsolicited AEs were assessed.
| Participants | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Any AE(s) | 146 | 148 | 93 | 76 | 97 | 104 |
| Possibly or Probably Related AE(s) | 25 | 31 | 23 | 16 | 18 | 27 |
Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported.
| Participants | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Any AE | 225 | 228 | 153 | 131 | 151 | 157 |
| Any Local AE | 224 | 227 | 148 | 129 | 148 | 156 |
| Any Systemic AE | 201 | 201 | 143 | 117 | 134 | 143 |
| Any Pain (1st vacc) | 213 | 223 | 142 | 126 | 80 | 146 |
| Grade 3 Pain (1st vacc) | 9 | 13 | 2 | 10 | 0 | 6 |
| Any Pain (2nd vacc) | 32 | 34 | 122 | 41 | 135 | 51 |
| Grade 3 Pain (2nd vacc) | 0 | 1 | 5 | 0 | 11 | 0 |
| Any Pain (3rd vacc) | 193 | 185 | 38 | 26 | 16 | 133 |
| Grade 3 Pain (3rd vacc) | 11 | 7 | 0 | 0 | 0 | 5 |
| Any Pain (4th vacc) | 79 | 77 | 19 | 106 | 44 | 138 |
| Grade 3 Pain (4th vacc) | 1 | 0 | 0 | 10 | 0 | 9 |
| Any Pain (5th vacc) | 83 | 80 | 58 | 48 | 119 | 64 |
| Grade 3 Pain (5th vacc) | 0 | 1 | 1 | 0 | 11 | 1 |
| Any Erythema (1st vacc) | 23 | 21 | 16 | 11 | 1 | 23 |
| Grade 3 Erythema (1st vacc) | 0 | 1 | 1 | 0 | 0 | 2 |
| Any Erythema (2nd vacc) | 3 | 5 | 8 | 1 | 17 | 2 |
| Grade3Erythema(2ndvacc) | 0 | 0 | 1 | 0 | 3 | 0 |
| Any Erythema (3rd vacc) | 32 | 27 | 0 | 2 | 0 | 19 |
| Grade3Erythema(3rdvacc) | 2 | 6 | 0 | 0 | 0 | 1 |
| Any Erythema (4th vacc) | 1 | 1 | 0 | 10 | 0 | 13 |
| Grade3Erythema(4thvacc) | 0 | 0 | 0 | 1 | 0 | 4 |
| Any Erythema (5th vacc) | 1 | 1 | 1 | 0 | 11 | 0 |
| Grade3Erythema(5thvacc) | 0 | 0 | 0 | 0 | 1 | 0 |
| AnyInduration(1st vacc) | 21 | 20 | 12 | 13 | 3 | 19 |
| Grade3Induration(1vacc) | 0 | 0 | 0 | 1 | 0 | 1 |
| AnyInduration(2nd vacc) | 2 | 2 | 10 | 0 | 11 | 2 |
| Grade3Induration(2vacc) | 0 | 0 | 0 | 0 | 0 | 0 |
| AnyInduration(3rd vacc) | 24 | 17 | 0 | 0 | 1 | 20 |
| Grade3Induration(3vacc) | 2 | 0 | 0 | 0 | 0 | 0 |
| AnyInduration(4th vacc) | 2 | 3 | 0 | 10 | 0 | 14 |
| Grade3Induration(4vacc) | 0 | 0 | 0 | 1 | 0 | 1 |
| AnyInduration(5th vacc) | 2 | 3 | 1 | 2 | 16 | 1 |
| Grade 3 Induration(5th vacc) | 0 | 0 | 0 | 1 | 1 | 0 |
| Any Fatigue (1st vacc) | 126 | 121 | 84 | 68 | 68 | 76 |
| Grade 3 Fatigue(1st vacc) | 7 | 7 | 4 | 3 | 3 | 4 |
| Any Fatigue (2nd vacc) | 61 | 64 | 64 | 40 | 64 | 49 |
| Grade 3 Fatigue(2nd vacc) | 0 | 3 | 4 | 2 | 1 | 0 |
| Any Fatigue (3rd vacc) | 106 | 96 | 44 | 32 | 32 | 55 |
| Garde 3 Fatigue(3rd vacc) | 4 | 5 | 1 | 0 | 1 | 1 |
| Any Fatigue (4th vacc) | 50 | 56 | 37 | 51 | 35 | 73 |
| Grade 3 Fatigue(4th vacc) | 2 | 3 | 0 | 5 | 2 | 3 |
| Any Fatigue (5th vacc) | 62 | 59 | 37 | 41 | 51 | 46 |
| Grade3Fatigue(5th vacc) | 1 | 2 | 4 | 0 | 6 | 3 |
| Any Headache (1st vacc) | 103 | 92 | 65 | 52 | 63 | 64 |
| Grade3Headache(1stvacc) | 4 | 3 | 5 | 2 | 2 | 3 |
| Any Headache (2nd vacc) | 67 | 47 | 70 | 36 | 63 | 41 |
| Grade3Headache(2ndvacc) | 1 | 2 | 3 | 2 | 4 | 2 |
| Any Headache (3rd vacc) | 90 | 76 | 42 | 28 | 30 | 53 |
| Grade3Headache(3rdvacc) | 3 | 4 | 1 | 0 | 3 | 0 |
| Any Headache (4th vacc) | 49 | 35 | 26 | 44 | 26 | 52 |
| Grade3Headache(4thvacc) | 3 | 3 | 0 | 2 | 0 | 4 |
| Any Headache (5th vacc) | 64 | 40 | 33 | 33 | 52 | 37 |
| Grade3Headache(5thvacc) | 1 | 1 | 2 | 1 | 2 | 2 |
| Any Myalgia (1st vacc) | 62 | 53 | 39 | 34 | 33 | 40 |
| Grade3Myalgia(1st vacc) | 2 | 4 | 2 | 2 | 0 | 3 |
| Any Myalgia (2nd vacc) | 15 | 20 | 27 | 15 | 37 | 18 |
| Grade3Myalgia(2nd vacc) | 0 | 3 | 1 | 1 | 1 | 0 |
| Any Myalgia (3rd vacc) | 52 | 40 | 13 | 10 | 13 | 34 |
| Grade3Myalgia(3rd vacc) | 2 | 2 | 0 | 0 | 2 | 2 |
| Any Myalgia (4th vacc) | 17 | 20 | 11 | 26 | 13 | 39 |
| Grade3Myalgia(4th vacc) | 1 | 1 | 1 | 2 | 0 | 2 |
| Any Myalgia (5th vacc) | 16 | 26 | 19 | 12 | 21 | 19 |
| Grade3Myalgia(5th vacc) | 0 | 1 | 0 | 0 | 1 | 1 |
| AnyAppetite Loss(1vacc) | 41 | 33 | 28 | 22 | 14 | 18 |
| Grade3AppetiteLoss(1vacc) | 2 | 3 | 0 | 0 | 0 | 0 |
| AnyAppetiteLoss(2vacc) | 17 | 11 | 15 | 12 | 19 | 9 |
| Grade3AppetiteLoss(2vacc) | 0 | 1 | 0 | 0 | 2 | 0 |
| AnyAppetiteLoss(3vacc) | 28 | 28 | 7 | 7 | 11 | 17 |
| Grade3AppetiteLoss(3vacc) | 1 | 0 | 1 | 0 | 1 | 0 |
| AnyAppetiteLoss(4vacc) | 11 | 10 | 4 | 13 | 11 | 23 |
| Grade3AppetiteLoss(4vacc) | 0 | 0 | 0 | 0 | 0 | 0 |
| AnyAppetiteLoss(5vacc) | 18 | 14 | 9 | 9 | 22 | 7 |
| Grade3AppetiteLoss(5vacc) | 0 | 0 | 1 | 0 | 0 | 0 |
| Any Nausea (1st vacc) | 42 | 36 | 28 | 17 | 26 | 21 |
| Grade 3 Nausea(1stvacc) | 1 | 0 | 0 | 0 | 0 | 1 |
| Any Nausea (2nd vacc) | 17 | 15 | 20 | 10 | 26 | 15 |
| Grade 3 Nausea(2nd vacc) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea (3rd vacc) | 35 | 24 | 10 | 8 | 4 | 21 |
| Grade 3 Nausea(3rd vacc) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea (4th vacc) | 21 | 13 | 9 | 11 | 14 | 23 |
| Grade 3 Nausea(4th vacc) | 1 | 0 | 0 | 0 | 0 | 0 |
| Any Nausea (5th vacc) | 16 | 15 | 8 | 11 | 21 | 12 |
| Grade 3 Nausea(5th vacc) | 0 | 0 | 0 | 0 | 0 | 0 |
| Any Chills (1st vacc) | 45 | 36 | 41 | 24 | 27 | 40 |
| Grade 3 Chills(1stvacc) | 1 | 0 | 1 | 1 | 2 | 1 |
| Any Chills (2nd vacc) | 17 | 26 | 26 | 12 | 32 | 15 |
| Grade 3 Chills(2ndvacc) | 0 | 1 | 1 | 0 | 0 | 0 |
| Any Chills(3rd vacc) | 33 | 33 | 9 | 7 | 12 | 22 |
| Grade 3 Chills(3rdvacc) | 1 | 1 | 0 | 0 | 1 | 0 |
| Any Chills(4thvacc) | 11 | 11 | 10 | 12 | 9 | 31 |
| Grade 3 Chills(4thvacc) | 2 | 0 | 0 | 0 | 0 | 1 |
| Any Chills (5th vacc) | 19 | 23 | 17 | 11 | 22 | 13 |
| Grade 3 Chills(5vacc) | 0 | 0 | 0 | 1 | 0 | 0 |
| Fever (1st vacc) | 5 | 4 | 5 | 1 | 2 | 3 |
| Fever (2nd vacc) | 2 | 6 | 4 | 2 | 9 | 3 |
| Fever (3rd vacc) | 6 | 3 | 2 | 0 | 4 | 4 |
| Fever (4th vacc) | 0 | 2 | 0 | 3 | 0 | 7 |
| Fever (5th vacc) | 5 | 1 | 2 | 0 | 3 | 1 |
| Pain/Fever prevention(1) | 28 | 34 | 21 | 26 | 5 | 34 |
| Pain/Fever prevention(2) | 5 | 7 | 18 | 5 | 24 | 7 |
| Pain/Fever prevention(3) | 32 | 34 | 3 | 2 | 3 | 21 |
| Pain/Fever prevention(4) | 6 | 5 | 3 | 19 | 3 | 25 |
| Pain/Fever prevention(5) | 5 | 9 | 4 | 1 | 26 | 3 |
| Pain/Fever treatment(1) | 31 | 45 | 27 | 32 | 6 | 31 |
| Pain/Fever treatment(2) | 3 | 4 | 20 | 3 | 29 | 4 |
| Pain/Fever treatment(3) | 38 | 37 | 2 | 4 | 2 | 23 |
| Pain/Fever treatment(4) | 7 | 4 | 2 | 22 | 2 | 27 |
| Pain/Fever treatment(5) | 3 | 8 | 2 | 3 | 29 | 2 |
| Any Arthralgia(1st vacc) | 25 | 14 | 13 | 17 | 12 | 14 |
| Grade3Arthralgia(1stvacc) | 0 | 1 | 0 | 0 | 1 | 2 |
| Any Arthralgia (2nd vacc) | 7 | 11 | 10 | 9 | 8 | 7 |
| Grade3Arthralgia(2ndvacc) | 0 | 0 | 0 | 1 | 0 | 1 |
| Any Arthralgia(3rd vacc) | 16 | 7 | 4 | 3 | 6 | 11 |
| Grade3Arthralgia(3rdvacc) | 0 | 1 | 0 | 0 | 0 | 0 |
| Any Arthralgia(4th vacc) | 8 | 10 | 5 | 10 | 7 | 18 |
| Grade3Arthralgia(4thvacc) | 1 | 0 | 0 | 0 | 0 | 2 |
| Any Arthralgia(5th vacc) | 8 | 9 | 8 | 6 | 11 | 11 |
| Grade3Arthralgia(5thvacc) | 0 | 0 | 0 | 0 | 0 | 0 |
The number of participants reporting any SAE, possibly or probably related SAE(s), medically-attended AEs, AEs leading to premature withdrawal, AEs leading to death, AEs leading to hospitalization and AEs leading to dose reduction, interruption and delay in study vaccination during the entire study period is reported.
| Participants | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Any SAE(s) | 9 | 3 | 8 | 7 | 2 | 6 |
| Possibly or Probably Related SAE(s) | 0 | 1 | 1 | 0 | 0 | 0 |
| Medically Attended AE(s) | 103 | 97 | 68 | 57 | 67 | 79 |
| AE(s) leading to premature withdrawal | 2 | 6 | 4 | 2 | 1 | 3 |
| AE(s) leading to Death | 0 | 0 | 0 | 0 | 0 | 0 |
| AE(s) leading to Hospitalization | 9 | 1 | 7 | 6 | 1 | 6 |
| AE(s)leadingtodosereduction,interruption,vaccdelay | 8 | 8 | 7 | 2 | 4 | 5 |
Collected over Solicited AEs were collected from day 1 to day 7, Unsolicited AEs were collected from day 1 to day 30, SAEs were collected throughout the entire study period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rMenB_0_2 Group | 0/228 (0%) | 9/228 (3.9%) | 226/228 (99.1%) |
| ABCWY_ 0_2 Group | 0/231 (0%) | 3/231 (1.3%) | 229/231 (99.1%) |
| ABCWY_0_1 Group | 0/155 (0%) | 8/155 (5.2%) | 153/155 (98.7%) |
| ABCWY_0_6 Group | 0/134 (0%) | 7/134 (5.2%) | 131/134 (97.8%) |
| ABCWY_0_11 Group | 0/151 (0%) | 2/151 (1.3%) | 151/151 (100%) |
| ABCWY_0_2_6 Group | 0/159 (0%) | 6/159 (3.8%) | 158/159 (99.4%) |
| Event | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 1/228 | 0/231 | 2/155 | 0/134 | 0/151 | 0/159 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 2/228 | 0/231 | 0/155 | 0/134 | 0/151 | 0/159 |
| Abdominal painGastrointestinal disorders | 0/228 | 0/231 | 1/155 | 1/134 | 0/151 | 0/159 |
| Crohn's diseaseGastrointestinal disorders | 0/228 | 0/231 | 0/155 | 1/134 | 0/151 | 0/159 |
| FatigueGeneral disorders | 0/228 | 0/231 | 0/155 | 1/134 | 0/151 | 0/159 |
| GastroenteritisInfections and infestations | 0/228 | 0/231 | 0/155 | 1/134 | 0/151 | 0/159 |
| TonsillitisInfections and infestations | 0/228 | 0/231 | 0/155 | 1/134 | 0/151 | 0/159 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 0/228 | 0/231 | 0/155 | 1/134 | 0/151 | 0/159 |
| Mental disorderPsychiatric disorders | 0/228 | 0/231 | 0/155 | 1/134 | 0/151 | 0/159 |
| Tooth extractionSurgical and medical procedures | 0/228 | 0/231 | 0/155 | 1/134 | 0/151 | 0/159 |
| Event | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group |
|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 221/228 | 225/231 | 148/155 | 129/134 | 148/151 | 154/159 |
| FatigueGeneral disorders | 169/228 | 165/231 | 119/155 | 98/134 | 105/151 | 120/159 |
| HeadacheNervous system disorders | 165/228 | 149/231 | 114/155 | 93/134 | 110/151 | 117/159 |
| Injection site erythemaGeneral disorders | 131/228 | 131/231 | 80/155 | 80/134 | 89/151 | 97/159 |
| Injection site indurationGeneral disorders | 110/228 | 98/231 | 67/155 | 53/134 | 70/151 | 85/159 |
| MyalgiaMusculoskeletal and connective tissue disorders | 103/228 | 99/231 | 69/155 | 54/134 | 65/151 | 81/159 |
| ChillsGeneral disorders | 80/228 | 76/231 | 61/155 | 40/134 | 62/151 | 70/159 |
| NauseaGastrointestinal disorders | 74/228 | 68/231 | 51/155 | 47/134 | 56/151 | 62/159 |
| Decreased appetiteMetabolism and nutrition disorders | 69/228 | 64/231 | 45/155 | 43/134 | 45/151 | 52/159 |
| Upper respiratory tract infectionInfections and infestations | 53/228 | 58/231 | 37/155 | 31/134 | 35/151 | 37/159 |
| Age, Continuous(Years) | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group | Total |
|---|---|---|---|---|---|---|---|
| Mean | 14.5 ± 3.09 | 14.2 ± 3.17 | 14.4 ± 3.01 | 14.4 ± 3.06 | 14.5 ± 3.1 | 14.3 ± 3.16 | 14.4 ± 3.1 |
| Sex: Female, Male(Participants) | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group | Total |
|---|---|---|---|---|---|---|---|
| Female | 130 | 119 | 101 | 76 | 89 | 96 | 611 |
| Male | 98 | 113 | 56 | 58 | 63 | 64 | 452 |
Ran from Aug 2014 to primary completion in May 2015, 9 months.
Results were first posted in Jul 2017, 2 years 1 month after primary completion. A results delay was requested in May 2015.
Of 18 phase 2 interventional studies under Meningococcal Infections, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 17. This study's 9 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 4CMenB vaccine · Meningococcal pentavalent vaccine